Risk factors for prevalent tuberculosis in HIV-infected patients attending a fee-for-service HIV clinic in inner city Johannesburg, South Africa by Connell, Lucy Shirley
  
i 
 
RISK FACTORS FOR PREVALENT TUBERCULOSIS IN 
HIV-INFECTED PATIENTS ATTENDING A FEE-FOR-
SERVICE HIV CLINIC IN INNER CITY JOHANNESBURG, 
SOUTH AFRICA 
 
 
Lucy Shirley Connell 
Student Number: 8600762P 
 
 
 
 
 
A research report submitted in partial fulfillment of the requirements for the 
degree of 
Master of Science in Epidemiology and Biostatistics 
 
University of the Witwatersrand, 
Faculty of Health Sciences, School of Public Health 
May, 2014 
 
 ii 
DECLARATION 
 
I, Lucy Connell, declare that this Research Report is my own work. It is being submitted 
for the degree of Master of Science in Epidemiology and Biostatistics at the University of 
the Witwatersrand, Johannesburg. No prior submissions of this material have been made for 
any degree or examination at this or any other university.  
 
 
 
 
 
---------------------------------------------------  
Lucy Connell 
  
9 May 2014
 iii 
ABSTRACT 
Introduction 
HIV-associated TB is curable with standard TB therapy and yet it is the leading cause of 
illness and death in patients infected with HIV. Coinfection with HIV poses considerable 
challenges to early diagnosis of TB in HIV-infected people and diagnostic delay and the 
rapidly progressive TB associated with HIV results in rapid clinical deterioration and 
increased mortality. There is an urgent need for research to identify risk factors for TB in 
HIV-infected people in order to refine diagnostic algorithms for the early and accurate 
diagnosis of tuberculosis in HIV-positive patients. 
The aim of this study was to determine the prevalence of TB, and identify factors 
associated with prevalent TB in HIV-infected adults paying a subsidized, all-inclusive 
monthly fee for HIV care in a private setting in downtown Johannesburg – a unique sub-
population.   
Material and Methods 
This study was a retrospective, cross-sectional, secondary analysis of data extracted from 
the routine electronic medical records of HIV-infected adults who attended ZuziMpilo from 
August 2009 to December 2011.  The outcome of interest was prevalent TB at the time of 
enrollment into care and exposures included age, sex, ethnicity, CD4 count, WHO Clinical 
Stage, BMI, alcohol and tobacco use history, level of education, employment status, 
monthly income, monthly cell phone expenditure, medical insurance status, source of 
funding for HIV care and source of knowledge about ZuziMpilo Medical Centre. 
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Multivariable logistic regression modeling was used to determine risk factors for prevalent 
TB at the time of enrollment. 
Results 
Approximately 8 out of every 100 HIV-infected adults enrolling at ZuziMpilo from August 
2009 to December 2011 had prevalent TB disease (8.24%). Significant predictors for 
prevalent TB included BMI categorised as non-obese, CD4 count <350 cells/mm
3
 and 
duration on HAART of less than six months. With respect to BMI, individuals who were 
not obese had greater risk of prevalent TB, the risk increasing in a dose response fashion as 
the BMI decreased. Compared to obese patients, overweight patients were 2.8 times as 
likely (aOR = 2.83, CI 1.06 – 7.52, p = 0.037), normal weight patients were more than 3.7 
times more likely (aOR = 3.72, CI 1.44 – 9.60, p = 0.007) and underweight patients were 
more than 6.4 times more likely to have prevalent TB (aOR = 6.42, CI 2.33 – 17.70, p = 
0.000). A CD4 count of < 200 cells/mm
3 
predicted an 11.3 times increased risk of prevalent 
TB relative to  CD4 count greater than 350 cells/mm
3
 (aOR = 11.27, CI 4.84 – 26.28, p = 
0.000). Patients treated with HAART for longer than 6 months were significantly less likely 
to have prevalent TB than HAART-naïve patients (aOR = 0.47, CI 0.23 – 0.98, p = 0.043).  
Conclusion and Recommendations 
This study corroborates the growing body of evidence that underpins several key 
recommendations that have the potential to reduce  mortality from TB in those people 
infected with HIV; vigilant and regular routine TB screening in HIV-infected patients at all 
CD4 counts and especially in those with profound immunosuppression and in the first three 
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to four months following HAART initiation, the urgent development and distribution of 
more sensitive and point of care diagnostic tests for TB in HIV-infected patients at all 
levels of health care (most especially primary health care facilities) and the importance of  
initiation of HAART before CD4 counts drop below 350 cells/mm
3
. This study highlights 
that BMI is a useful proxy marker of TB risk among HIV-positive individuals. Height and 
weight are easily assessed anthropomorphic measures and should be conducted routinely in 
all patients at regular intervals.  
This study has described a unique population with the capacity to pay a subsidised monthly 
fee for their HIV care and thus the results may not be generalisable to the large population 
of HIV-infected adults in South Africa, who receive free-of-charge health care in public 
sector facilities. However, they may certainly be generalisable to other clinics that provide 
services for a fee and this information may be especially important if this model is 
replicated and scaled up in private and semi-private facilities around the country.  
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GLOSSARY 
AFB Acid-fast bacillus. This term is a synonym for bacteria of the Genus 
Mycobacteria, which includes the causative organism of 
tuberculosis, M. tuberculosis, and refers to the physical property of 
retaining colourant dyes despite washing with acid. 
AIDS    Acquired Immunodeficiency Syndrome 
BMI   Body mass index  
CD4    CD4 cell or T4 helper lymphocyte    
CI   Confidence interval 
CSV   Comma separated value 
ETR.Net  Electronic Tuberculosis Register 
HAART  Highly active antiretroviral treatment 
HIV   Human immunodeficiency virus 
NHLS    National Health Laboratory Service  
NICD   National Institute for Communicable Diseases  
IRR   Incidence rate ratio  
IQR    Interquartile range 
OR   Odds ratio 
PEPFAR   Presidents Emergency Plan for AIDS Relief 
Prevalent TB The term refers to the number of existing TB cases identified at a 
specific point in time, in contrast to the number of new TB cases 
identified within a specific time period (incident TB). In this study 
the term has a specific definition related to the time frame and 
evidence for the diagnosis. 
 xv 
SD    Standard deviation 
SNTB Culture-confirmed tuberculosis that was initially sputum smear-
negative  
TB   Tuberculosis 
WHO   World Health Organisation 
WHO Clinical Stage World Health Organisation-devised classification of HIV disease 
into four progressive clinical stages reflecting deteriorating immune 
system function. (1)  
ZuziMpilo  ZuziMpilo Medical Centre
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1. INTRODUCTION 
This chapter illustrates the burden of TB and HIV coinfection and provides a justification 
for this study, presenting a literature review that explores the reported TB prevalence 
among HIV-infected individuals attending dedicated HIV clinics and discussing evidence 
for factors reported to predict TB in the general population and among HIV-infected 
populations specifically. 
1.1. Background  
1.1.1. The burden of TB globally and in sub-Saharan Africa 
Tuberculosis (TB) remains the leading infectious cause of death worldwide, despite major 
progress in reducing the number of TB cases and deaths in the past two decades (2). This is 
particularly true in Africa, a region responsible for a quarter (25%) of the 8.7 million new 
cases of TB reported in 2011 (2). This follows an unprecedented surge in the incidence of 
TB in sub-Saharan Africa in particular, fuelled largely by the HIV epidemic, where annual 
TB incidence has doubled and the number of TB cases and TB-related deaths has tripled 
since 1990 (3). 
 
1.1.2. HIV and TB coinfection 
HIV infection is the most potent risk factor for tuberculosis and drives the TB epidemic at 
population level (4-7). A recent World Health Organization (WHO) analysis of the 
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proportion of TB cases coinfected with HIV confirms that HIV-infected individuals are 20 
times more likely than HIV-seronegative people to develop active TB in countries with 
high HIV prevalence (8). The increased risk of TB disease in HIV-infected individuals 
manifests soon after infection, doubling within the first year after HIV infection, even 
before CD4 counts decline (9). The rising prevalence of HIV has dramatically increased the 
incidence of TB, both in people living with HIV as well as possibly indirectly in those who 
are HIV-negative because of the increased pool of infectious individuals in the population 
(10).. 
 
1.1.3. HIV and TB in South Africa 
South Africa has the highest number of people infected with HIV in the world (11), with an 
estimated 5.6 million HIV-infected individuals in 2011(12). According to the WHO Global 
Tuberculosis Report 2012, the country also has the highest TB incidence rate; 993 per 100 
000 in 2011 (2).  Many patients with TB are coinfected with HIV. In 2011, 65% of the TB 
patients for whom HIV status was known were coinfected with HIV (2).   
The incidence of TB appears to be dropping since it reached a peak in 2009. The District 
Health Barometer reports a trend of decreasing numbers of new cases of pulmonary smear-
positive TB since 2009 (13). Similarly, recent analysis by the National Institute for 
Communicable Diseases (NICD), of all the microbiological testing undertaken for 
suspected TB cases between 2004 and 2012, conducted exclusively by the National Health 
Laboratory Service (NHLS), showed that national TB incidence (including pulmonary and 
extra-pulmonary TB) peaked in 2009 and subsequently decreased to 2006 rates by 2012.  
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The reduction in TB rates since 2009 correlates with the scale up in the ART programme, 
despite the lack of decline in HIV prevalence rates over the same period (14).   
 
1.1.4. HIV-associated TB Mortality 
The syndemic interaction between HIV and TB has deadly consequences around the world 
(15). TB is the leading cause of morbidity and mortality in HIV-infected adults in sub-
Saharan Africa (7, 16). HIV-infected people have more rapidly progressive TB and a higher 
TB-associated mortality than their HIV-negative counterparts (17, 18). Thus, in 2011, HIV-
associated TB accounted for 31% of deaths among incident TB cases globally, even though 
only 13% of all incident cases were coinfected (2). 
HIV-infection alters the clinical and radiological presentation of TB, making diagnosis 
more difficult (19, 20). Consequently, active TB is often not diagnosed in HIV-infected 
patients, a reality borne out by evidence arising from postmortem studies of HIV/AIDS 
patients in several sub-Saharan African countries, including South Africa. These studies 
reveal extremely high proportions of deaths with undiagnosed and often disseminated TB 
(21-23). It is likely that official figures underestimate the contribution of TB to mortality in 
HIV-infected patients.  
 
1.1.5. Diagnosis of TB 
Sputum smear microscopy, the traditional method of diagnosing TB rapidly, is less 
sensitive in HIV-infected patients because they have frequently pauci-bacillary disease, i.e., 
 4 
fewer acid fast bacilli (AFB) detectable in their sputum (24, 25). HIV-infected adults with 
TB are twice as likely to have sputum smear-negative but culture positive TB, compared 
with HIV negative adults (26). Atypical clinical presentations and radiological features, 
together with reduced sensitivity of sputum smear microscopy and long waiting time (2 to 6 
weeks) for mycobacterial culture results contribute to delayed diagnosis of TB in HIV-
infected patients (27). Moreover, smear-negative TB (SNTB) has worse prognosis (28) in 
part due to delays in diagnosis and treatment initiation (27).  However, rapid, accurate, 
novel molecular methods to diagnose TB have recently become available. South Africa is 
the leading adopter of the WHO-endorsed Xpert MTB/RIF, a rapid molecular test that can 
diagnose TB and rifampicin resistance within 100 minutes (2). Despite the national roll out 
of Xpert MTB/RIF  in South Africa since March 2011, sputum smear microscopy remains 
the mainstay of diagnosis in many facilities countrywide (29). 
 
Data from the South African electronic TB register (ETR.Net) bear witness to the high 
proportion of missed TB diagnoses in HIV positive patients (30). In 2007, burgeoning 
access to direct measurements of the prevalence of HIV in TB patients worldwide 
prompted the revision of  the risk of developing TB in HIV-positive patients as compared 
with HIV-negative patients in countries with high prevalence, generalized HIV epidemics. 
The incidence rate ratio (IRR) was revised upwards from 6 to 20.6 (8).  However, in the 
2010/2011 financial year, only 67.7%, of newly diagnosed HIV-infected patients 
(approximately 940 000 of 1.4 million) were screened for TB. Over the same period the 
District Health Information System recorded 100 000 new HIV-positive patients with 
confirmed TB (7.1%). Although the higher rates of smear negative TB in HIV-positive 
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individuals, under reporting and poor data quality contribute to this low rate of HIV-
positive patients with confirmed TB, the large gap between the number of expected and 
reported cases is yet another confirmation of the extent to which TB is under diagnosed in 
HIV-positive patients (13). 
 
1.1.6. ZuziMpilo Medical Centre  
The ZuziMpilo Medical Centre (ZuziMpilo) is a private clinic in downtown Johannesburg 
that offers fee-for-service health care for people living with HIV. ZuziMpilo offers 
voluntary counselling and testing for HIV, a wellness programme that caters for HIV-
infected people who are not yet eligible for antiretroviral treatment and antiretroviral 
treatment.  The setting of ZuziMpilo, and the TB-related services it offers, is described in 
more detail in Chapter 2, Material and Methods. 
 
1.2. Statement of problem 
HIV-associated TB is curable with standard TB therapy (15) and yet it is the leading cause 
of illness and death in the 5.6 million South Africans estimated to be infected with HIV. 
Coinfection with HIV poses considerable challenges to early diagnosis of TB in HIV-
infected people. In the face of diagnostic delay, rapidly progressive TB associated with 
HIV can result in rapid clinical deterioration and increased mortality, especially in those 
with low CD4 counts. Early and accurate diagnosis of tuberculosis in HIV-positive patients 
is needed to improve individual treatment outcomes and reduce transmission (19). The 
 6 
identification of risk factors for TB in HIV-infected people can help refine diagnostic 
algorithms for tuberculosis screening resulting in earlier detection of active TB and 
identification of patients eligible for isoniazid preventive therapy. The need for such 
research is urgent. 
 
1.3. Justification for the study 
This patient population used for this study is unusual as it represents a niche sector of the 
HIV-infected population, distinct from that in either private or public sector health 
facilities:  individuals who elect not to use state facilities but cannot afford to use private 
health facilities. Studies have sought to identify risk factors of TB in HIV-infected patients 
and use these to develop clinical diagnostic algorithms to reduce diagnostic delays, costs 
and TB-related morbidity and mortality (31, 32). Most of these studies have taken place in 
public sector facilities with potentially very different patient population profiles. There has 
only been one study published that examined TB prevalence among HIV infected patients 
enrolling in a fee-for-service health facility in South Africa, as opposed to public sector 
facilities. This was a prospective study conducted at McCord’s Zulu Hospital. a semi-
private hospital in Durban, described by Hom et al (33).  ZuziMpilo differs from the clinic 
described in that study because the monthly fee for HIV care at ZuziMpilo is at least four 
times that paid at McCord’s Hospital. The higher ZuziMpilo monthly fee potentially selects 
for patients in more affluent economic circumstances with possible implications for TB 
prevalence patterns. Furthermore, the focus of the Durban study was the prevalence of drug 
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resistant TB and the determination of resistance patterns, rather that the determination of 
predictors of prevalent TB. 
If the ZuziMpilo model of charging a subsidized, all-inclusive monthly fee for HIV care in 
a private setting proves to be sought-after, acceptable and sustainable, it may be replicated 
across the country and it will be important to understand TB prevalence patterns and 
predictors of TB in the populations who seek care in such facilities. This study includes a 
unique sub-population that differs both from populations that use state facilities and from 
more wealthy populations with health insurance or medical aid, and determined the 
prevalence of TB within clients attending the clinic to identify risk factors associated with 
prevalent TB.  
 
1.4. Literature Review 
1.4.1. The burden of TB in ART services 
The prevalence of TB/HIV coinfection is highest in the sub-Saharan region of the African 
continent, ranging from 8.4% in Ethiopia to 77% in Swaziland, in 2011 (2). On the other 
end of the spectrum, in wealthier regions with low HIV burdens, such as Europe and North 
America, the risk of incident TB is so low that current guidelines for the management of 
HIV-infected adults do not  recommend routine screening for TB at HAART initiation, 
although the European guidelines do recommend screening for latent TB infection at the 
time of HIV diagnosis (34, 35). For instance, in 2011, when the incidence rate for TB was 
993 per 100 000 population in South Africa, the TB incidence rates for the entire WHO 
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region of the Americas, France and Germany were 28, 4.3 and 4.5 per 100 000 population 
respectively (2). An observational cohort study of 48 854 patients who started HAART 
between 1996 and 2009, from 12 cohorts in Europe, USA and Canada, found higher rates 
of  AIDS defining events, most commonly TB, in migrants rather than non-migrants. Not 
unexpectedly, these differences were most marked among migrants from sub-Saharan 
Africa as opposed to North Africa/Middle East, Latin America and Asia (36). These results, 
and the results of similar studies, have prompted authors to highlight the importance of 
screening for TB at HAART initiation in low TB burden countries, especially in migrant 
populations (36, 37). 
 
The reported prevalence of TB in HIV-infected adults attending outpatient HIV clinics 
across South Africa varies from 8% to 42.5% (38-44), likely reflecting: different case 
definitions for prevalent TB used in these studies, varying regional TB prevalence rates, the 
proportion of TB patients tested for TB, the effectiveness of referral networks between TB 
and ART services and the thoroughness of pre-HAART TB screening (42).  Most studies 
have reported on the proportion of patients with TB diagnoses at initiation of HAART and 
include two groups of patients; those who first present to health services with TB and are 
referred to HAART services after they are tested and diagnosed with HIV and those HIV-
positive patients who enroll in HAART services who are diagnosed with TB during 
preparation for HAART initiation (45).  
Table 1.1 summarizes the findings of six South African studies that report estimates of TB 
prevalence in adults enrolling at dedicated HIV clinics across the country. The prevalence 
of TB in patients enrolling in HAART services has risen sharply following an intensive 
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campaign in the public sector to increase provider initiated testing and counselling for HIV  
(42, 43).  In two Cape Town townships, the TB prevalence rose from approximately 23% to 
43% between 2001 and 2007 in Kayelitsha (42)  and from approximately 16% to 35% 
between 2002 and 2008 in Gugulethu (43). It is important to note that these areas carry an 
extremely high burden of TB. In 2003, during the period of retrospective review for both 
these studies, the annual TB notification rate in Cape Town Metro was 1000/100 000 (46). 
Yet in the same year, the antenatal HIV seroprevalence rate for the Western Cape province 
was 13.1%, well below the national average of 28% (47). 
 
Table 1-1: Summary of reported prevalence of TB in HIV-infected adults attending 
outpatient HIV clinics across South Africa. 
Time period and 
setting 
Description of study 
population and method 
Case definition Proportion with TB Median CD4 count 
(all participants)  
Reference 
April 2004 to March 
2007 
Suburban 
Johannesburg, 
Gauteng  Province 
 
7,066 HIV-infected adults 
attending a dedicated HIV 
clinic at a public sector 
tertiary hospital  
 
Retrospective analysis 
Prevalent TB at the time of 
HAART initiation, including 
individuals: 
 already on TB treatment 
 starting TB treatment 
concurrently with 
HAART 
 Starting TB treatment 
within 60 days of 
HAART initiation 
 
23.0% 
(1628/7066) 
 
Already on TB 
treatment: 
59  cells/mm3 
(IQR 23 – 116) 
Starting TB 
treatment and 
HAART 
concurrently: 
48  cells/mm3 
(IQR 13 – 112) 
Westreich 
et al, 2009 
(39) 
May 2001 to 
December 2007 
Khayelitsha 
township, Western 
Cape 
 High levels of 
poverty 
 High HIV and TB 
burden 
7,323 HIV-infected 
patients 14 years and 
older attending 3 public 
sector primary health 
clinics  
 
Retrospective analysis 
Prevalent  TB at HAART 
initiation defined as 
individuals already on TB 
treatment  
2001/2002: 
22.7% 
(65/286) 
 
2007: 
42.5% 
(789/1860) 
2001/2002: 
42.5 cells/mm3 
(IQR 13 – 95) 
 
2007: 
131 
(IQR 64 – 191) 
Boulle et al. 
2010 (42) 
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Time period and 
setting 
Description of study 
population and method 
Case definition Proportion with TB Median CD4 count 
(all participants)  
Reference 
 
July 2003 to 
December 2008 
Suburban Soweto, 
Gauteng  Province 
 
3,456 HIV-infected adults 
attending a dedicated HIV 
clinic at a public sector 
tertiary hospital  
 
Retrospective analysis 
Prevalent TB at the time of 
the baseline visit, 
including individuals: 
 already on recorded TB 
treatment 
 with laboratory 
confirmation of TB  
 admitted to hospital with 
a diagnosis of TB 
 
8% 
(95% CI 18 – 21) 
 
 
285  cells/mm3 
(IQR 153 - 452) 
Hanrahan 
et al, 2010 
(40) 
September 2002 
and June 2008 
Gugulethu 
township, Western 
Cape Province 
 High levels of 
poverty 
 High HIV and TB 
burden 
 
 
3,770 HAART-naïve adult 
patients attending a 
dedicated public sector 
ART clinic 
 
Retrospective analysis 
Prevalent TB at time of 
enrollment into service 
defined as individuals 
already receiving TB 
treatment at time of 
enrollment. 
 
September 2002 to 
June 2005: 
16.0% 
(95% CI 13.9 - 18.1) 
 
July 2007 to June 
2008: 
34.7%  
(95% CI 31.4 - 38.1) 
September 2002 to 
June 2005: 
99  cells/mm3 
(IQR 48 – 154) 
 
July 2007 to June 
2008: 
120  cells/mm3  
(IQR 56 – 186) 
Lawn et al,  
2011 (43) 
May 2007 to May 
2008 
Suburban Durban, 
KwaZulu-Natal  
Province 
Highest HIV 
prevalence in the 
country (37.4% in 
the province vs. 
28.0% in the whole 
country in 2007) 
1,035 HIV-infected adults  
attending a dedicated HIV 
clinic semi-private 
hospital, paying a monthly 
subsidized fee 
 
Prospective cohort study 
Prevalent TB at the time of 
enrollment (HAART 
initiation) defined as 
individuals already 
receiving TB treatment at 
time of enrollment into 
study. 
 
 
18% 
(191/1035) 
78  cells/mm3 
(IQR 40 – 125) 
Hom et al, 
2012   
August 2007 and 
January 2008 
Urban Klerksdorp 
and rural 
surrounds,  
North West 
High HIV 
prevalence (31.8%) 
381 HIV-infected adults 
referred for HAART 
initiation to a dedicated 
HIV clinic at a public 
sector hospital. 
Prospective cohort study 
Prevalence of TB at the 
time of enrollment into 
study (HAART initiation), 
or within 3 months of 
enrollment, defined as: 
Compatible clinical or 
radiological features of 
TB with: 
 Laboratory confirmation 
of  M. tuberculosis, or 
32% 
(95% CI 26.8 – 36.6) 
120  cells/mm3 
(IQR 72 – 168) 
Hanifa et al, 
2012 (44) 
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Time period and 
setting 
Description of study 
population and method 
Case definition Proportion with TB Median CD4 count 
(all participants)  
Reference 
 No laboratory 
confirmation and clinical 
improvement after 2 
months of anti-
tuberculosis treatment 
and no other cause of 
disease found 
Patients taking anti-
tuberculosis treatment at 
the time of enrollment or 
within the previous three 
months were excluded. 
 
Analysis of 7066 patients attending a large public sector HIV clinic in Johannesburg 
revealed a prevalence of TB in patients initiating HAART of 23.04% (95% CI 22.06 – 
24.04). The definition of prevalent TB included individuals already on TB treatment at the 
time of HAART initiation, those starting TB treatment concurrently with HAART and 
those newly diagnosed within 60 days of HAART initiation (39).  In a study that explored 
the association between body mass index (BMI) and the risk of tuberculosis and death at a 
Soweto HIV clinic, the baseline prevalence of TB in a cohort of 3456 HIV-infected adults 
was 8% (95% CI 18 – 21) (40).  The case definition of TB in this study included 
individuals with laboratory confirmed TB, recorded initiation of TB treatment or 
hospitalisation with a diagnosis of TB. In a prospective cohort study designed to investigate 
the prevalence of, and evaluate screening modalities for, undiagnosed TB in HAART-
eligible adult patients referred to an HIV clinic at a public sector hospital in Klerksdorp in 
the North West province, the prevalence of undiagnosed active TB at enrollment or within 
3 months after enrollment was 32% (95% CI 26.8 – 36.6) (33). In this study the case 
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definition for prevalent TB was tighter than those used for the other studies quoted. Patients 
were classified as having TB if they had compatible symptoms and signs of TB and M. 
tuberculosis cultured from any site (definite TB), compatible symptoms and signs of TB 
and other laboratory evidence for TB (Probable TB) or compatible symptoms and signs of 
TB, no laboratory evidence for TB and clinical improvement after two months of TB 
treatment (Possible TB). Because the focus of the study was undiagnosed TB, all patients 
already on TB treatment at the time of enrollment, and those who had been on TB treatment 
within the previous three months, were excluded. The last mentioned study was conducted 
in a dedicated HIV clinic at a semiprivate hospital serving a primarily urban population in 
Durban, KwaZulu-Natal. This study site was unique among the 5 studies referenced in that 
the clinic in question charged a subsidized fee for service which, during the study period, 
amounted to an all-inclusive monthly fee of ZAR90. This was a cross-sectional cohort 
study designed to estimate the prevalence of drug-resistant TB and describe resistance 
patterns in adults starting HAART. Of the 1035 patients recruited, 20% (210) were already 
on TB treatment at the time of enrollment and 18% (191) were sputum positive for M. 
tuberculosis. Table 1.1 highlights an important association between the median CD4 counts 
of the study populations and the estimates of TB prevalence, evident despite the varying 
case definitions used to define TB prevalence. The study that reports the lowest by far 
prevalence also reports the highest, by far, median CD4 count. The median CD4 count for 
the study at a non-fee paying HIV Wellness clinic at a tertiary public sector hospital in 
Soweto was 285 cells/mm
3
 (IQR 153 – 452). In comparison, the other four studies, 
conducted in Kayelitsha, Gugulethu, Johannesburg and Durban reported median CD4 
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counts that range from 42 to 131 cells/mm
3 
and TB prevalence rates that range from 16% to 
43%. 
Mozambique and Zambia had similar TB/HIV coinfection rates to South Africa in 2011, 
63%, 64% and 65% respectively (2).  In both countries, studies have reported a TB 
prevalence of approximately 11% among HIV-infected adults initiating HAART between 
2004 and 2006 and from 2004 to 2005 respectively (48, 49).  In marked contrast, the 
HIV/TB coinfection rate in Burkina Faso to the north was 17% (2).  Not surprisingly, the 
incidence of TB in the months following HAART initiation are much lower than one would 
expect from the countries further south with far higher levels of TB/HIV coinfection.  In a 
retrospective study that included 2383 HIV-infected adults initiating HAART in four 
different HIV treatment centres, 96%  of HIV positive patients were still on HAART and 
free of TB at the end of the first year of follow-up (50). 
1.4.2. Risk factors for TB 
Poverty, overcrowded dwellings, poorly ventilated workplaces, poor nutrition, and lack of 
access to quality health care are well-recognized drivers of TB transmission and are thought 
to be similarly important for HIV-associated TB (6, 51). These are features of slum life to 
which increasing numbers of South Africans are exposed as the population urbanizes 
rapidly without concomitant economic development and prosperity (52). A study published 
in 2007, based on an analysis of 13,043 Demographic Health Survey (1998) respondents, 
examined the demographic and behavioural risk factors for prevalent TB in the general 
population. Cigarette smoking, alcohol consumption, low body mass index (BMI), a lower 
level of personal education, unemployment, and lower household wealth were associated 
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with statistically significant increased odds of a diagnosis of TB (53).  It is unlikely that 
people who seek care at ZuziMpilo, a fee-for-service health facility, are as exposed to the 
poor socio-economic factors as those with no other choice but to use public-sector health 
facilities. 
 
Studies of risk factors for TB in HIV-infected people have identified advanced 
immunodeficiency (low CD4 cell count and WHO Clinical Stage 3 or 4) and high plasma 
viral load as the most important risk factors associated with both prevalent and incident TB 
(38, 39, 41, 54, 55). Unlike in HIV seronegative populations, the prevalence of TB 
appeared not to change with increasing age in three large South African cohorts of adults 
attending large state-run HIV services (38, 39, 41, 54, 55).  However, a recent analysis of 
NHLS data from 2004 to 2012 showed that there was a significant difference in the 
incidence of microbiologically confirmed TB across broad age categories; the highest rates 
were seen in the 25 to 44 year old age groups (14). 
 
In many populations, the prevalence of TB in men and women differs across different age 
groups, with an excess TB risk in young women and old men. (56, 57) However, overall, in 
most regions of the world, adult men are more likely to develop active TB than adult 
women (58). Globally in 2011, the male-to-female ratio of case notifications of new smear 
positive cases was 1.7 and in South Africa it was 1.3 (2).  This gender difference persists 
even in large, systematic epidemiological studies that take into account potential 
confounders that could influence case notification rates, such as differential health seeking 
behaviours, access to health care services, exposure to smoking, alcohol and mine dusts and 
 15 
other pollutants, etc. (58). For example, a three-country case-control study in West Africa 
published in 2005 and a household survey of more than 260,00 individuals in Bangladesh 
published in 2004 confirmed male sex as a risk factor for TB, independent of 
socioeconomic, environmental, cultural and host-related potential confounding factors (59, 
60). In a recent study in the Western Cape of South Africa, male sex was an independent 
predictor of latent TB infection among adolescents in a high TB burden area (61).  In this 
study, the prevalence of HIV was not measured but was expected to be low, reflecting the 
low (5 to 10%) annual antenatal HIV seroprevalence estimates for the area (relative to the 
much higher (30%) national antenatal seroprevalence.   Several other studies in South 
Africa have picked up the similar sex difference among HIV-infected adults. Male sex was 
found to be a significant independent predictor of TB prevalence at the time of HAART 
initiation in two large cohorts (7000 and 3770 respectively) attending public sector HIV 
clinics in Johannesburg and Gugulethu township, Cape Town (41, 43). Similarly, male sex 
was an independent risk factor for a baseline history of TB at HAART initiation in a 
prospective cohort of 1771 members (and their dependents) of the South African National 
Defence Force attending military HAART services (38, 54, 55).  
 
A previous history of TB has been found to be partially protective for prevalent TB at the 
time of HAART initiation, the more recent the episode, the greater the protection, in two of 
the studies mentioned above, both the Johannesburg and Gugulethu cohorts (39, 41, 54)  
 
There is a great deal of evidence for low BMI as a predictor of disease progression and 
mortality among HIV infected adults (62-64) and by inference, for tuberculosis which is the 
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leading cause of death among those living with HIV in Africa (65). There is also strong 
evidence for a direct relationship between increasing BMI and reduced risk for 
tuberculosis. In a cohort study of 3635 HIV-infected adults in a Soweto HIV wellness 
clinic, high BMI (specifically overweight and obese BMI) was shown to be strongly 
protective against incident TB and all-cause mortality, after adjusting for CD4 cell count 
and HAART use (40).  Similarly, underweight BMI was identified as an independent risk 
factor for prevalent TB in this Johannesburg cohort (41) and in a Ugandan study (66).  
Unemployment was identified a risk factor for prevalent TB in the Gugulethu cohort (41).  
 
HAART is strongly associated with a marked reduction in TB incidence in adults with HIV 
across all CD4 counts (45, 67-69). This response is dependent on the duration of treatment. 
Within the first 6 to 12 months after HAART initiation the risk for TB diminishes rapidly, 
mirroring the magnitude of immune recovery as reflected in rising CD4 counts. A large 
cohort study in a Cape Town township in South Africa, examined TB incidence stratified 
by serially updated CD4 counts during HAART and compared TB incidence during early 
(< 4 months) and long term (> 4 months) HAART. The study revealed a strong, graded, 
independent association between TB risk and updated CD4 counts; the adjusted TB rate 
associated with the lowest CD4 stratum, <100 cells/mm
3
, was more than nine-fold greater 
than the rate associated with the highest stratum, >500cells/mm3 (70).  The study also 
documented a now well-established finding that TB incidence remains exceptionally high 
in the first months after initiating HAART, even after adjusting for CD4 count and viral 
load. Among patients with CD4 cell counts < 200 cells/mm
3
, there was a 1.7-fold excess 
adjusted TB incidence rate during early HAART compared with during long-term 
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treatment. The study suggests that much of the TB burden in the first few months after 
HAART initiation is due to the “unmasking” of asymptomatic or minimally symptomatic 
disease that was present on initiation of HAART but missed during screening (45). This 
phenomenon, known as the immune reconstitution inflammatory syndrome (IRIS), occurs 
when rapid restoration of pathogen-specific immune responses causes either the 
paradoxical deterioration of a treated infection or triggers the new and often florid 
presentation of previously subclinical infection (71). IRIS occurs in 10 – 27% of patients 
initiating HAART and typically occurs in the first few months after initiation (72).  
Unfortunately, multiple studies have observed that, despite the steady decline with long 
term HAART, TB incidence remains elevated relative to the background incidence seen in 
the general population, despite many years of HAART therapy (67, 70). 
 
1.5. Study Objectives 
1.5.1. Overall objective  
To determine the prevalence of TB, and identify factors associated with prevalent TB in 
HIV-infected adults attending ZuziMpilo.  
 
1.5.2. Specific objectives 
 To describe the characteristics at enrolment of the study population represented by all 
those who attended ZuziMpilo in the period from August 2009 to December 2011, 
including demographic, socio-economic status and anthropometric variables as well as 
variables indicating HIV disease progression and substance use history. 
 18 
 To determine the proportion of HIV-infected adults with prevalent TB at enrolment in 
those who attended ZuziMpilo in the study period. 
 To investigate whether any of the characteristics mentioned above independently predict 
prevalent TB in this population. 
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2. MATERIALS AND METHODS 
This chapter describes the study design, the study population and selection of the study 
sample, the data sources mined, definitions of outcome and exposure variables, the 
statistical methods employed to analyse the data and ethical considerations. 
 
2.1. Study design 
This was a cross sectional, secondary analysis of data extracted from the routine electronic 
medical records of HIV-infected adults who attended ZuziMpilo from August 2009 to 
December 2011.   
 
2.2. Study setting 
The ZuziMpilo Medical Centre (ZuziMpilo) is a private clinic in downtown Johannesburg - 
at the time of the study funded by the Presidents Emergency Plan for AIDS Relief 
(PEPFAR) - that offers fee-for-service health care for people living with HIV.  It was 
conceived by the Perinatal HIV Research Unit in 2006 to fill the gap between public and 
private sector HIV care. ZuziMpilo is targeted primarily at employed adults without 
medical aids who prefer not to use state health facilities (73). 
ZuziMpilo offers voluntary counselling and testing for HIV, a wellness programme that 
caters for HIV-infected people who are not yet eligible for HAART and antiretroviral 
treatment.  Symptom-based TB screening with immediate investigation of those who have 
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symptoms, onsite TB therapy initiation and referral to public-sector facilities for ongoing 
TB therapy, and monitoring for clinical response to TB therapy are standard of care 
services offered to HIV-infected patients at ZuziMpilo.  During the study period, 
ZuziMpilo charged patients an all-inclusive monthly fee for their care that increased from 
ZAR430 in August 2009 to ZAR600 in December 2011 (74). 
ZuziMpilo is situated in the densely populated Johannesburg inner city. According to the 
Community Survey conducted in 2007, the population of the City of Johannesburg 
Metropolitan Municipality as a whole was 3,888,180 (75). In the inner city alone, some 248 
599 residents live in 97 484 households and around 1 million commuters enter the inner 
city every day. In 2009, the average household monthly income of inner city residents was 
approximately R6, 389.10 (76). The antenatal HIV seroprevalence in the City of 
Johannesburg Municipality was 29.6% in 2010, close to the Gauteng provincial and 
national prevalence estimates (30.4% and 30.2% respectively) (77).  In the same year, the 
annual incidence rate for all types of TB in the Municipality was 630 per 100 000, below 
the national average of 805 per 100 000.  
 
2.3. Study sample 
The study sample was selected based on non-random sampling including all HIV-infected 
adults, 18 years and older, who were enrolled consecutively into care at ZuziMpilo in the 
28 months, from 1 August 2009 to 31 December 2011. Although ZuziMpilo started 
enrolling patients into care from 2006, August 2009 was selected as the start of the study 
period because from this date it became standard procedure to collect detailed baseline 
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information from patients. Thus, for patients enrolled since the beginning of August 2009, 
there is additional data related to a range of characteristics including; occupation, income, 
education, medical aid membership, financing of medical care, alcohol and tobacco use.  
 
2.4. Data source 
The data used from this study were those collected for routine medical care; they were not 
collected for research purposes.  ZuziMpilo uses TherapyEdge
TM
, an HIV-specific rapid 
data collection system or electronic medical record, to capture patient data electronically in 
real-time during consultations. Information about a patient may be collected by at least 
three different staff members at each visit:  
1. At the initial visit, an administrative clerk collects socio-demographic and referral 
data and completes a survey that collects information that includes:  previous 
exposure to antiretroviral treatment, alcohol use and smoking, employment, 
monthly all source-income, monthly cell phone expenditure, medical aid 
membership, financing of care at ZuziMpilo and how the patient came to know 
about ZuziMpilo.  
2. A nurse captures information about: past medical and surgical history and 
symptoms and enters height and weight measurements if done.  
3. Finally, a doctor captures information relating to:  additional medical history, the 
clinical examination findings, diagnosis and treatment.  
Most blood tests results are automatically entered into TherapyEdge
TM
 by the laboratory 
staff. 
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It is standard procedure at the clinic to screen all HIV-infected patients at their first visits, 
and regularly thereafter, for symptoms and signs of TB using a simple questionnaire and a 
physical examination. According to standard operating procedure, three consecutive 
sputum samples for acid-fast bacilli microscopy and culture should be collected for those 
with suspected TB. Patients are referred offsite for additional diagnostic tests, such as chest 
radiography and mycobacterial evaluation of cerebrospinal fluid, pleural fluid and lymph 
node biopsy specimens, as indicated. Patients diagnosed with TB are registered, initiated on 
TB treatment and referred to state TB services for notification and treatment continuation. 
Patients on TB treatment remain in care at ZuziMpilo and are monitored for clinical 
improvement. 
 
2.5. Definitions 
Definitions of study variables were established a priori - before the data was analysed. 
Table 2.1 below summarises the nature of each variable. 
2.5.1. Exposure variables  
We were interested in risk factors for prevalent TB.  Therefore, the values selected for these 
variables, such as WHO Clinical Stage, height and weight, and CD4 count, etc, were the 
nearest measurement to the date of the first visit and for the purposes of this study were 
restricted to within 60 days prior to, or following, the date of the first ZuziMpilo visit. 
 Baseline BMI - calculated from the measurements for height and weight (BMI=height 
cm /weight
 
(kg) squared) taken on the visits nearest to the first visit date and falling 
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within a period of 60 days prior to and post the first visit date. Baseline BMI was 
stratified into 4 categories based on the World Health Organization classification of 
adult BMI: underweight (BMI <18.5 kg/m
2
), normal weight (BMI 18.5–25 kg/m2), 
overweight (BMI 25.1–30 kg/m2) and obese (BMI >30 kg/m2) (78). 
 Baseline CD4 cell count (cells/mm3) - defined as the value nearest to the first visit date 
and within a period of 60 days prior to, or following, the first visit date. CD4 count was 
stratified into the following categories: < 200 cells/mm
3
, 200 – 349 cells/mm3 and > 350 
cells/mm
3
. 
 WHO Clinical Stage (1) – the value for this parameter was taken from the visit nearest 
to the first visit date and falling within a period of 60 days prior to, or  following, the 
first visit date. WHO Clinical Stage was categorized into Stage 1 - 4. 
 HAART status – defined as whether the participant had previous or current exposure to 
HAART or not and categorised as follows: HAART naïve or has started HAART.  
 Period of exposure to HAART – defined as the number of completed months that the 
participant had ever taken combination antiretroviral therapy at the first visit date.   
 Smoking history – defined as the self-reported number of cigarettes or pipes that the 
participant smoked per week, self reported at the time of the first visit. 
 Alcohol history - defined as the self-reported number of alcoholic drinks the participant 
consumes per week at the time of the first visit.   
 Level of education – defined as the highest level of education attended and categorised 
into 3 categories; primary school, secondary school and tertiary education. 
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 Employment – defined as the participant’s most recent (within the past year) or current 
employment history and was categorised as follows:  unemployed, full-time employed, 
self-employed, part-time jobs, student and pensioner. 
 Source of knowledge about ZuziMpilo – defined as the source of the information 
when the participant heard about ZuziMpilo for the first time, with 5 categories as 
follows; partner, family or friend, employer or workplace, health worker or health 
facility, mass media and internet. 
 Health insurance – defined as whether the participant had health insurance or medical 
aid at the time of the first visit or not. 
 Monthly all-source income – defined as average monthly income from any source and 
was categorised into 3 categories; less than R1,000/month, R1,000 -R4,999/month and 
R5,000 or more/month. 
 Monthly cell phone expenditure – this was categorised into 2 categories: zero cell 
phone expenditure - R200/month, and >R200/month. Monthly cell phone expenditure 
was used as proxy for disposable income. 
 Source of payment for care – defined as person responsible for payment to ZuziMpilo; 
and divided into two categories: self-funded and funded by another person. 
 
2.5.2. The outcome variable 
The outcome of interest was prevalent TB. Prevalence was defined in relation to the first 
visit date. A diagnosis of prevalent TB, as opposed to incident TB, was defined as a 
diagnosis of TB made: 
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 Within 91 days prior to the first visit to ZuziMpilo or 
 At the first visit   
 Within 61 days following the first visit  
The rationale for this time frame is as follows: Selecting patients diagnosed within a 91 day 
window prior to the first visit identifies “current” TB episodes and excludes “previous” 
diagnoses and patients who would most likely already have rising CD4 counts in response 
to TB treatment. Selecting patients diagnosed within a 61 day window after the first visit 
identifies patients who most likely had TB disease that was missed during enrolment 
screening.  
Participants diagnosed with prevalent TB were then classified into one of five diagnostic 
categories as follows (79): 
 Culture confirmed TB; defined as the presence of clinical signs and symptoms of 
tuberculosis and a positive culture for Mycobacterium tuberculosis from any site. 
 Probable TB; defined as the presence of clinical signs and symptoms with acid-fast 
bacilli on a sputum smear or caseous necrosis in a tissue-biopsy specimen. 
 Possible TB; defined as the presence of clinical signs and symptoms without 
microbiological or histological evidence of M. tuberculosis but with a documented 
clinical response to antituberculosis therapy (e.g. symptoms diminishing and/or increase 
in weight) 
 Suspected TB; defined as the presence of clinical signs and symptoms without 
microbiological or histological evidence of M. tuberculosis and without documentation 
of a clinical response to antituberculosis therapy. 
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 Not TB; defined as the presence of clinical signs and symptoms of tuberculosis without 
microbiological or histological evidence of M. tuberculosis but with microbiological 
evidence of alternative mycobacterial species, for example, M. avium complex. 
Hard copy and electronic clinical records were searched for the evidence needed to classify 
cases as above, including laboratory reports and data from subsequent visits that indicated 
the presence or absence of a clinical response to TB treatment. If no laboratory reports 
could be found in the clinical records, the National Health Laboratory Service database was 
scrutinized for any evidence of a laboratory diagnosis of TB (microbiology, histology and 
cytology reports).  
It was anticipated that there might be several patients who would remain classified as 
having “Suspected TB”, despite considerable efforts to mine source documents and local 
laboratories for information that would allow them to be included in the study case 
definition. Such patients were excluded from the study definition. This approach is similar 
to the case definition used in a recently published prospective cohort study, conducted by 
Hanifa et al, to determine the prevalence of previously undiagnosed TB among ART-
eligible adults at a public sector hospital HIV clinic in Klerksdorp, Gauteng Province. (44) 
 
Table 2-1: Summary of the outcome and exposure variables 
Variable Coding 
Prevalent TB 0 = Not diagnosed with prevalent TB or diagnosed with TB and classified as Suspected TB or Not TB  
1 = Diagnosed with TB and classified as Confirmed TB, Probable TB or Possible TB 
Age (in completed years) The difference between the date of birth and the date of the first visit 
Sex 1 = Male 
2 = Female 
BMI (kg/m2) Categorized according to the WHO International Classification of Adult BMI: 
1 = Underweight (BMI <18.5) 
2 = Normal (BMI 18.5–25) 
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Variable Coding 
3 = Overweight (BMI 25.1–30) 
4 = Obese (BMI >30) 
WHO Clinical Stage 1 = WHO Stage 1 
2 = WHO Stage 2 
3 = WHO Stage 3  
4 = WHO Stage 4 
CD4 cell count (cells/mm3) 1 = < 200 
2 = 200 – 349 
3 = >350 
Months on HAART 1 = HAART naive 
2 = HAART for < 6 completed months 
3 = HAART for> 6 months 
History of current smoking  
 
1 = No smoking 
2 = < 7 cigarettes/week 
3 = > 7 cigarettes/week 
History of current alcohol use 1 = No alcohol 
2 = < 6 drinks/week 
3 = > 6 drinks/week 
Highest level of education achieved 1 = Primary school 
2 = Secondary school 
3 = Tertiary education 
Employment status 1 =  Unemployed 
2 =  Not unemployed (includes the formally employed, self-employed, pensioners and students) 
Monthly all-source income 1 = < R1,000  
2 = R1,000 – R4,999  
3 = > R5,000  
Monthly cell phone expenditure 1 = R0 to R200 
2 = >R200 
Medical aid membership 0 = No 
1 = Yes 
Source of payment for consultations 1 = Self 
2 = Funded by other 
Source of knowledge about ZuziMpilo 1 = Workplace 
2 = Health facility 
3 = Mass media  
4 = Partner, family or friend 
 
NOTE:  Some categories were defined by TherapyEdge TM electronic record.    
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2.6. Data Analysis  
2.6.1. Data preparation and cleaning 
TherapyEdgeTM (v. 3.2, TherapyEdge Inc, Massachusetts, USA) data is stored in a 
MySQL database. ZuziMpilo data for the study period was exported in eight comma 
separated value (CSV) files. The CSV files were imported into STATA (STATA Statistical 
Analysis package, v. 11.0; College Station, Texas, USA), via MS Excel, for coding, 
cleaning, merging and statistical analysis. The export of the main demographic 
questionnaire was not in tabular format but contained a list of questions, unique patient 
identifiers and responses in text format. This file was converted using a Python (v. 2.6; 
Beaverton, USA) script and Python dictionaries to convert the file into a usable CSV file. 
Using a document that outlines the TherapyEdge database structure (80), it was possible to 
merge multiple files using unique linking variables.  
 
TherapyEdge
TM
 was not designed primarily as a research data capture tool and, despite the 
numerous logical and range checks designed to facilitate accurate and complete data entry, 
implausible and missing values presented significant analytical obstacles. The dataset was 
screened for duplicated observations which were removed and missing and inconsistent 
values. Range checks, box and whisker plots and histograms were used to identify outliers, 
implausible values and unexpected distributions with continuous variables. An attempt was 
made to decrease the number of missing values and obtain valid values for variables with 
implausible values by manually checking source documents at ZuziMpilo - clinical and 
laboratory records - both electronic and hard copies of source documents. Additionally, for 
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certain clinical variables, for example; height and weight for BMI calculation, CD4 count 
and WHO Clinical Stage, the value from the visit closest in time and within a defined time 
limit (appropriate to the variable in question) of the first visit date. Clearly implausible 
values were recorded as missing when the above data validation measures were 
unsuccessful.  
 
2.6.2. Descriptive statistics 
The study population was described in terms of age, gender, BMI, baseline CD4 cell count, 
WHO Clinical Stage, exposure to HAART, occupational status, monthly income, cell 
phone expenditure, medical aid membership, smoking history, alcohol history. The mean 
and standard deviation, or the median with its interquartile range were used to summarise 
continuous variables for normal or non-normally distributed data respectively. Frequencies 
(n) and percentages (%) were used for categorical variables. The overall prevalence of TB 
was reported with its 95% confidence intervals (95% CI) and then for subcategories of 
patients.  
 
2.6.3. Inferential statistics  
Each of the variables was tested for association with prevalent TB, using the two sample t-
test for the means of continuous variables and the Pearson’s chi-square test for the 
frequency and distribution of categorical variables and univariate logistic regression. Any 
variable with a P value < 0.20 in the univariate analysis was included in the multiple 
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variable regression model, as well as those with p > 0.20 that had biological plausibility for 
and established importance as predictors of TB in the literature.  Adjusted Odds Ratios 
(aORs) with p > 0.050 were considered not statistically significant in the multivariable 
analysis. Interaction terms were introduced into the model to explore effect modification 
and confounding. 
 
To ensure that the final regression model satisfied the assumptions of logistic regression 
and produced valid statistical inferences, the model was subjected to diagnostic tests to 
evaluate the model for specification error (linktest), how well the model fitted the data (log 
likelihood chi-square and pseudo R-square Hosmer and Lemeshow’s goodness-of-fit test), 
multicollinearity between exposure variables (collin), the presence of influential points and 
the extent of the influence of these influential points on the regression equation (81).     
Statistical significance was set at 0.05 (two tailed).   
 
2.6.3.1. Dealing with missing variables  
Missing data may bias conclusions about the size and existence of associations between the 
outcome variable and exposure variables (82). In this study, missing data was a 
consequence of information not gathered or evaluations not performed during visits, patient 
non-attendance of visits and the recoding of implausible values as missing. Analysis of 
missing values using Chi-squared tests was done to investigate whether missing data were 
associated with the outcome (Prevalent TB) and is presented in Appendix 6.1. In addition to 
the above analysis, all analyses exploring associations between exposure variables and the 
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outcome of interest were conducted using two different datasets, one that assigned a unique 
category for missing values within each variable and one that did not. This allowed for 
assessment of systematic differences between the datasets in the bivariate and univariate 
regression analysis. In the final multivariable regression models, the dataset that assigned 
unique categories to missing values was used to prevent the exclusion of individuals from 
the model who had missing values for any variables.  
2.6.3.2. Testing the validity of the study case definition 
A sensitivity analysis to explore the effect of excluding patients classified as having 
“Suspected TB” from the study case definition was carried out. This alternative analysis 
included these patients in the study case definition for prevalent TB. The results are 
displayed in Appendix 6.2.  
 
2.7. Sample size 
A sample size of 1800 was assumed to evaluate the adequacy of the study sample based on 
the total of 1967 individuals enrolled into care at ZuziMpilo during the period 1 August 
2009 to 31 December 2011 (29 months), allowing for the exclusion of children under 18 
years of age. The reported TB prevalence for public sector HIV clinics in Johannesburg 
ranges from 8% to 20% (39, 40).  With respect to the precision of the measure of TB 
prevalence in a sample of 1800, with an estimated TB prevalence at enrolment in the study 
population assumed to be 10% (towards the lower estimate in the range of reported 
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prevalence), would enable a point estimate of TB prevalence with its 95% confidence 
intervals of 1.2% (absolute) on either side of this estimate.  
With respect to identification of predictors of prevalent TB, exposure to HAART is used as 
an example. Assuming that 80% of participants were not yet on HAART (the exposure) at 
their first ZuziMpilo visit, and assuming that the prevalence of TB in the unexposed group 
is 10%, with a sample size of 1800, this study will be powered at 80% to detect an odds 
ratio of 1.72. Thus a sample size of at least 1 800 will be sufficient to carry out the 
proposed descriptive and inferential statistics at the stated significance and power levels.  
 
2.8. Ethical considerations 
Patients at ZuziMpilo give signed informed consent at their first visit, using a generic form 
approved by the University of the Witwatersrand’s Human Research Ethics Committee 
(Medical), for their data to be used for research (Clearance certificate number: M070361), 
see Appendix 3. Participant confidentiality was protected by removing unique numeric 
identifiers and personal identifiers from the dataset prior to analysis. This was a 
retrospective record review and the study posed minimal risk to clients of ZuziMpilo. The 
Postgraduate Committee and the Human Research Ethics Committee, Faculty of Health 
Sciences, University of Witwatersrand approved this analysis (Clearance certificate 
number: M10M101177), see Appendix 6.5.  
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3. RESULTS 
During the period between 1 August 2009 and 31 December 2011 (29 months), 1967 
individuals were enrolled into care at ZuziMpilo. Seventy-four patients younger than 18 
years old were excluded, yielding a final dataset of 1893 individuals of 18 years or older.  
Of the 266 patients diagnosed with TB during the study period, 202 (75.9%) met study 
criteria for a prevalent TB as opposed to an incident TB diagnosis. Of these 202 patients, 26 
(13.3%) were diagnosed within 91 days prior to their first clinic visit, 30 (15.4%) were 
diagnosed at their first clinic visit and 139 (71.38%) were diagnosed within 61 days after 
their first clinic visit. Detailed examination of source documents (laboratory data and 
clinical records) to classify TB cases in terms of the study case definition of prevalent TB 
showed that 156 patients fulfilled the study definition for TB,  yielding an overall TB 
prevalence at enrollment of 8.24% (95% Confidence Interval (CI) 7.04 – 9.57).  Figure 3.1 
below illustrates the inclusion of patients in the study sample and their classification in 
terms of the study outcome, Prevalent TB. 
 34 
Figure 3-1: Flow chart illustrating the inclusion of patients in the study sample and 
the classification in terms of the study outcome, Prevalent TB
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For 39 patients who had been diagnosed with TB, there was insufficient evidence for a 
definitive classification as either “Possible TB” or “Suspected TB”. Of these 39 patients, 14 
had subsequent visits but not within the period of 25 to 70 days post the date of diagnosis 
which is the time period within which clinical improvement could have been assessed. 
Three were transferred out and three died, at 14, 18 and 23 days after diagnosis 
respectively. These patients were excluded as Prevalent TB cases.  
Table 3.1 shows the timing of the various classifications of TB diagnoses. The majority of 
patients with study-defined prevalent TB were diagnosed with TB at ZuziMpilo (84.6%), 
either at the first visit (12.2%) or within 61 days thereafter (72.4%). Just above 15% were 
diagnosed before referral to ZuziMpilo. Almost all (95.9%) of the 39 patients for whom 
there was insufficient evidence for classification with respect to the study definition of 
prevalent TB were diagnosed empirically at ZuziMpilo. 
 
Table 3-1: The timing of TB diagnoses of patients within various diagnostic 
classifications. 
 
Classification TB diagnosed 
before referral 
TB diagnosed at 
1st visit 
TB diagnosed after  
first visit 
Confirmed TB (%) 4 (2.56) 7 (4.49) 76 (48.72) 
Probable TB (%) 3 (1.92) 2 (1.28) 8 (5.13) 
Possible TB (%) 17 (10.90) 10 (6.41) 29 (18.59) 
Total with TB (%) 24 (15.38) 19 (12.18) 113 (72.14) 
Insufficient evidence for 
TB diagnosis (%) 2 (5.13) 11 (28.21) 26 (66.67) 
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3.1. Analysis of missing values 
There were no missing values for the variables “Age”, “Sex” and “Time on HAART”. The 
variable which has the highest proportion of missing values was “WHO Clinical Stage” 
with 823 missing values (43.48%). For all remaining variables included in the database, the 
proportion of missing values was below 20%. Table 3.1 presents the characteristics of the 
overall study sample and includes the number and proportion of missing values for each 
exposure variable. Missing data were associated with prevalent TB for the variables “WHO 
Clinical Stage” and “BMI”.  For “WHO Clinical Stage”, patients for whom a value for WHO 
Stage had been recorded had a significantly higher prevalence of TB than patients with missing 
values for WHO Stage (P < 0.050). Similarly, for “BMI”, patients for whom both height and 
weight were recorded had a significantly higher prevalence of TB than patients with missing 
values (P < 0.050).  
The data presented in this chapter derives from analysis conducted using a dataset that 
assigned missing values a unique category in each variable. A sensitivity analysis was 
conducted using a dataset that did not include missing values in a separate category for 
each variable. The results for the contingency analysis and univariate logistic regression 
were comparable with respect to the direction and magnitude of the associations.  
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3.2. Description of the patient population  
3.2.1. Demographic characteristics 
The median age of the 1893 patients was 32 years (IQR 26 - 38) and 60.2% were women. 
The median age of women (30 years [IQR 25 – 37]) was significantly younger (p < 0.000) 
than that of men (34 years [IQR 29 – 40]). The majority of patients were Black Africans 
(91.8%) with other ethnic groups; Whites, Coloureds and those classified as “Other”, each 
representing less than 1% of the patient population.  
 
3.2.2. Clinical characteristics, HIV disease progression indicators, and tobacco and 
alcohol consumption history 
At enrollment, over a third (37.8%) of all individuals had normal BMIs, over a third 
(36.6%) were obese or overweight and 8.3% were underweight. Significantly more (p < 
0.000) women were obese or overweight than men; 16.9% of women compared to 5.7% of 
men were obese (p < 0.000) and 25.3% of women compared to 22.4% of men were 
categorized as overweight. Approximately a fifth (21.5%) of patients was classified as 
WHO Clinical Stage 3 or 4. Overall, the median CD4 count was 239 cells/mm
3
 (IQR 110 – 
405) and 38.8% of patients had profound immunosuppression with a CD4 count < 200 
cells/mm
3
). The majority of patients (83.4%) were HAART naïve and 16.6% had already 
started HAART prior to their first visits to ZuziMpilo. Of those who had started HAART 
prior to enrollment at ZuziMpilo, the majority (74.0%) had been on HAART for more than 
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6 months. The majority (86.5%) of patients with an enrollment CD4 count below 200 
cells/mm
3
 had not yet started HAART (p < 0.000).  
 
3.2.3. Socioeconomic, educational and other characteristics 
Over half the sample population (57.4%) had reached tertiary education (partial or 
complete), 28.4% had received secondary education level and 8.0% had received primary 
education. The majority of patients (75.0%) was employed or had income in the form of 
pensions or support while studying while a fifth (20.9%) were unemployed. Approximately 
a fifth, (21.6%) earned less than R1000 a month from all sources, 31.7% earned between 
R1000 and R5000 a month and 28.8% earned more than R5000 a month. Just under two 
thirds (63.4%), reported spending less than R200/month on cell phone/s. The majority of 
patients (73.3%) did not have health insurance and, at enrollment, most patients (69.5%) at 
ZuziMpilo made out-of-pocket payments while the cost of care for 204 individuals (10.8%) 
was paid for by someone other than themselves (employer, family member, friend, etc.). 
Patients were most likely to have heard about ZuziMpilo from a partner, family member or 
friend (28.8%), the mass media (25.2%) or a health facility (24.0%) than from the 
workplace (2.8%). 
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Table 3-2: Characteristics of adult HIV-infected patients enrolled at ZuziMpilo 
Medical Centre from 1 August 2009 to 31 December 2011 
 
 
Characteristic   
 Median IQR 
Age (median, IQR) 32 26 - 38 
CD4 count (median, IQR) 239 110 - 405 
 N % 
Sex   
Male 1140 60.22 
Female 753 39.78 
Ethnicity   
Black 1737 91.76 
Coloured 16 0.85 
White 12 0.63 
Other 3 0.16 
Missing 125 6.6 
BMI     
Obese 236 12.47 
Overweight 457 24.14 
Normal weight 715 37.77 
Underweight 155 8.19 
Missing 330 17.43 
WHO stage   
Stage 1 288 15.21 
Stage 2 375 19.81 
Stage 3 272 14.37 
Stage 4 135 7.13 
Missing 823 43.48 
CD4 count     
>350 553 29.21 
201 to 350 463 24.46 
<200 734 38.77 
Missing 143 7.55 
HAART Status   
Not on ART 1578 83.36 
Started ART 315 16.64 
Months on HAART   
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Characteristic   
HAART naive 1578 83.36 
HAART < 6 months 82 4.33 
HAART > 6 months 233 12.31 
Smoking   
No smoking 1587 83.84 
<7 cigarettes/week 114 6.02 
>7 cigarettes/week 85 4.49 
Missing 107 5.65 
Alcohol use     
No alcohol 1371 72.42 
<6 drinks/week 237 12.52 
>6 drinks/week 137 7.24 
Missing 148 7.82 
Level of education   
Primary school 152 8.03 
Secondary school 537 28.37 
Tertiary education 1086 57.37 
Missing 118 6.23 
Employment status   
Unemployed 1418 74.91 
Not unemployed

 394 20.81 
Missing 81 4.28 
Monthly income   
< R1,000 409 21.61 
R1,000 to R4,999 600 31.7 
> R5,000 546 28.84 
Missing 338 17.86 
  
R0 to R200 1200 63.39 
>R200 335 17.7 
Missing 358 18.91 
Medical Aid     
Has medical aid 174 9.19 
No medical aid 1387 73.27 
Missing 332 17.54 
Financing of care     
Self-funded 1315 69.47 
Funded by other 204 10.78 
Missing 374 19.76 
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Characteristic   
Knowledge of service     
Workplace 52 2.75 
Health facility 454 23.98 
Mass media 476 25.15 
Partner, family or friend 545 28.79 
Missing 366 19.33 
 Not unemployed = employed (full-time, part-time and self-employed), pensioners and students 
 
 
3.3. Associations between patient characteristics and prevalent TB in HIV-
infected adults enrolling at ZuziMpilo 
The following patient characteristics were found to be significantly associated with 
Prevalent TB; sex, BMI, WHO Clinical Stage, CD4 count, duration on HAART, 
employment status, monthly income, financing of care and source of knowledge about 
ZuziMpilo. Table 3.2 outlines the results of contingency table using Pearson’s 2 test,, the 
Fischer’s exact test for categorical variables with any category containing less than five 
values and the Student’s t-test for normally distributed continuous variables.   
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Table 3-3: Associations between patient characteristics and Prevalent TB 
 
 
 
Characteristic Prevalent TB 
(n=156) 
No TB 
(n=1737) P value

 
Age Median (IQR) Median (IQR)  
 31  (26 – 38) 32.5  (28 – 38) 0.357

 
Age N  (%) N  (%)  
< 30 years  704  (93.00) 53  (7.00) 0.099 
30 to 39.9 years  662  (90.07) 73  (9.93)   
> 40 years  371  (95.52) 30  (7.48)  
Sex    
Female, n (%) 82  (7.19) 1058  (92.81) 0.041 
Male, n (%) 74  (9.83) 679  (90.17)   
Ethnicity    
Black 148  (8.52) 1589  (91.48) 0.234

 
Coloured 1  (6.25) 15  (93.75)  
White 2  (16.67) 10  (83.33)  
Other 0  (0.00) 3  (100)  
Missing 5  (4.00) 120  (96.00)  
BMI    
Obese 5  (2.12) 231   (97.88) 0.000 
Overweight 33   (7.22) 424   (92.78)   
Normal weight 81   (11.33) 634   (88.67)   
Underweight 36   (23.23) 119   (76.77)   
Missing 1   (99.7) 329   (99.70)   
WHO stage    
Stage 1 7  (2.43) 281  (97.57) 0.000 
Stage 2 17  (4.53) 358  (95.47)   
Stage 3 61  (22.43) 211  (77.57)   
Stage 4 37  (27.41) 98  (72.59)   
Missing 34  (4.13) 789  (95.87)   
CD4 count      
>350 547  (98.92) 6  (1.08) 0.000 
201 to 350 446  (96.33) 17  (3.67)   
<200 609  (82.97) 125  (17.03)   
Missing 135  (94.41) 8  (5.59)   
HAART status    
HAART naïve 136  (8.62) 1442  (91.38) 0.181 
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Characteristic Prevalent TB 
(n=156) 
No TB 
(n=1737) P value

 
Stared HAART 20  (6.35) 295  (93.65)   
Months on HAART    
HAART naive 136  (8.62) 1442  (91.38) 0.011 
HAART < 6 months 11  (13.41) 71  (86.59)   
HAART > 6 months 9  (3.86) 224  (96.14)   
Smoking    
No smoking 129  (8.13) 1458  (91.87) 0.149 
<7 cigarettes/week 5  (4.39) 109  (95.61)   
>7 cigarettes/week 11  (12.94) 74  (87.06)   
Missing 11 (10.28) 96  (89.72)   
Alcohol use      
No alcohol 120  (8.75) 1251  (91.25) 0.295 
<6 drinks/week 12  (5.06) 225  (94.94)   
>6 drinks/week 11  (8.03) 126  (91.97)   
Missing 13  (8.78) 135  (91.22)   
Level of education    
Primary school 12  (7.89) 140 (92.11) 0.239 
Secondary school 55  (10.24) 482  (89.76)   
Tertiary education 79  (7.27) 1007  (92.73)   
Missing 10  (8.47) 108  (91.53)   
Employment status    
Not unemployed

 109  (7.69) 1309  (92.31) 0.027 
Unemployed 44  (11.17) 350  (88.83)   
Missing 3  (3.70) 78  (96.30)   
Monthly income    
< R1,000 46  (11.25) 363  (88.75) 0.050 
R1,000 to R4,999 51  (8.50) 549  (91.50)   
> R5,000 36  (6.59) 510  (93.41)   
Missing 23  (6.80) 315  (93.20)   
Cell phone expenditure 
R0 to R200 108  (9.00) 1092  (91.00) 0.271 
>R200 22  (6.57) 313  (93.43)   
Missing 26  (7.26) 332  (   
Medical Insurance      
Has medical insurance 14  (8.05) 1268  (91.42) 0.614 
No medical insurance 119  (8.58) 160  (91.95)   
Missing 23  (6.93) 309  (93.07)   
Financing of care      
Self-funded 100  (7.60) 1215  (92.400 0.002 
Funded by other 30  (14.71) 174  (85.29)   
Missing 26  (6.95) 348  (93.05)   
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Characteristic Prevalent TB 
(n=156) 
No TB 
(n=1737) P value

 
Knowledge of service      
Workplace 5  (9.62) 47  (90.38) 0.014 
Health facility 33  (7.27) 421  (92.73)   
Mass media 28  (5.88) 448 (94.12)   
Partner, family or friend 63  (11.56) 482  (88.44)   
Missing 27  (7.38) 339  (92.62)   
 
 All P values are for Pearson’s 2 test for categorical variables except where indicated otherwise. 
 Student’s t-test for a normally distributed continuous variable 
 Fisher’s exact test 
 Not unemployed = employed (full-time, part-time and self-employed), pensioners and students 
 
Men were more likely to have prevalent TB than women (9.8% of men vs. 7.2% of 
women, p = 0.041). Patients with normal and underweight BMI were more likely to have 
TB at enrollment, 11.3% and 23.2% respectively, compared with patients with overweight 
and obese BMI, 7.2% and 2.1% respectively, (p = 0.000). 
 
Although many patients did not have recorded assessments of WHO Clinical stage, 
patients with advanced WHO Staging were more likely to have TB at enrollment. Of those 
classified as WHO Stages 1 and 2, 2.4% and 4.5% respectively were diagnosed with 
prevalent TB in comparison with those classified as WHO Stages 3 and 4, of whom 22.4% 
and 27.4% respectively were diagnosed with prevalent TB (p = 0.000). Patients with a very 
low CD4 count were far more likely to have prevalent TB than those with higher CD4 
counts. While 17.0% of patients with a CD4 count < 200 cells/mm
3 
had prevalent TB, 
patients with higher CD4 counts at enrollment, 201 to 350 cells/mm
3
 and > 350 cells/mm
3
, 
had TB prevalence rates of 3.7% and 1.1% respectively. While there was no significant 
difference with respect to the rate of prevalent TB between those who were HAART naïve 
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and those already on HAART at enrollment (p = 0.181), there was a significant difference 
when the duration of HAART exposure was considered. Patients who had been on 
HAART for 6 months or less at enrollment were more likely (13.4%) to have prevalent TB 
than those who had been on HAART for more than 6 months (3.9%), (p = 0.011).  
 
With respect to employment status, the group of patients without employment was 
significantly more likely (11.2%) to have prevalent TB than those who were employed or 
had an income in the form of a pension or support while studying (7.7%) (p = 0.027). 
Similarly, a higher proportion of patients with monthly incomes below R1, 000 (11.3%) 
had prevalent TB compared with those who reported a monthly income of R1, 000 to R4, 
999 (8.5%) and more than R5, 000 (6.6%), (p = 0.050). Those patients who did not cover 
the cost of their care at ZuziMpilo themselves were twice as likely (14.7%) to have 
prevalent TB compared to those who did fund their own care (7.6%), (p = 0.002). 
Patients who had heard about ZuziMpilo from a partner, family member or friend were 
more likely (11.6%) to have TB at enrollment than patients who had heard about ZuziMpilo 
from the workplace (9.6%), a health facility (7.3%) or from the mass media (5.9%) , ( p = 
0.014). 
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3.4. Determining risk factors for Prevalent TB in adult HIV-infected patients 
enrolling at ZuziMpilo  
3.4.1. Univariate logistic regression 
Univariate logistic regression analysis (Table 3.3) confirmed most of the significant 
associations identified by contingency table analysis above (Table 3.2), elucidated the 
nature and magnitude of these potentially predictive relationships and informed the design 
of the final multivariate regression model. In the unadjusted analysis, as for contingency 
table analysis, significant risk factors for prevalent TB included sex, BMI, WHO Clinical 
Stage, CD4 count, months on HAART, employment status, monthly income and financing 
of care. However, in contrast to the contingency table analysis, age was identified as an 
additional predictor for prevalent TB using univariate logistic regression while source of 
knowledge about ZuziMpilo was not. 
 
3.4.2. Significant risk factors  
While there was no significant relationship between age and the rate of prevalent TB using 
contingency table analysis, age was revealed to be a significant predictor of prevalent TB 
using univariate logistic regression. Patients in their thirties were 46% more likely than 
patients under 30 years of age to have prevalent TB (OR = 1.46,   CI 1.01 – 2.12, p = 
0.043). Males were more likely to have prevalent TB than females (OR = 1.41, CI 1.01 – 
1.95, p = 0.042). Relative to obese patients, patients who were overweight (OR = 3.60 CI 
1.38- 9.34, p = 0.009), normal weight (OR = 5.90, CI 2.36 – 14.75, p = 0.000), or 
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underweight (OR = 13.98, CI 5.35 – 36.55, p = 0.000) were increasingly more likely to 
have prevalent TB, suggesting a strong dose response relationship.  
The risk of prevalent TB increased with advancing WHO Clinical Stage, relative to WHO 
Clinical Stage 1 or asymptomatic HIV disease. The lower the CD4 count at enrollment, the 
greater the risk of prevalent TB; patients with CD4 counts between 200 and 350 cells/mm
3 
were more likely to have prevalent TB than those with CD4 counts above 350 cells/mm
3
 
(OR = 3.48, CI 1.36 – 8.89, p = 0.009).  The risk was even greater for those with CD4 
counts of 200 cells/mm
3 
and below (OR = 18.71, CI 8.18 – 42.79, p = 0.000). 
Patients who were unemployed were 51% more likely to be diagnosed with TB at 
enrollment than those who were not unemployed (OR = 1.51, CI 1.04 – 2.18, p = 0.029).  
Patients who did not fund their care at ZuziMpilo themselves were twice as likely to have 
prevalent TB as those who financed their care themselves (OR = 2.09, CI 1.35 – 3.25, p = 
0.001). 
 
3.4.3. Significant protective factors 
Patients who had been on HAART for longer than 6 months were 57% less likely to have 
prevalent TB compared with patients who were HAART-naïve (OR = 0.43, CI 0.21 – 0.85, 
p = 0.015). Compared with patients who earned an income of less than R1, 000/month, 
those who earned a monthly income greater than R5, 000 were 44% less likely to have 
prevalent TB. (OR = 0.56, CI 0.35 – 0.88, p = 0.007). 
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3.4.4. Multivariate logistic regression 
The final multivariate logistic regression model (Table 3.3) included all variables with a p 
value < 0.2 and included the following variables: age, sex, BMI, CD4 count, smoking 
history, alcohol use history, employment status, monthly all-source income, monthly cell 
phone expenditure and source of funding for ZuziMpilo care. WHO Clinical Stage was 
excluded from the model because TB is one of the most common staging conditions for 
WHO Clinical Stages 3 and 4.  
 
There was no collinearity between any of the variables (Appendix 6.2).  The highest 
Spearman’s correlation coefficients were between income and cell phone expenditure (ρ = 
0.61) and medical insurance and cell phone expenditure (ρ = 0.62).  The multivariable 
regression analysis was repeated restricting inclusion of variables to those with p < 0.050 
on the univariate logistic regression.  However, diagnostic tests evaluating the models for 
specification error, goodness of fit and the presence and influence of influential points 
favoured the initial model which included all variables with p < 0.20.  
 
BMI, CD4 count and duration of exposure to HAART emerged as significant predictors of 
prevalent TB, adjusting for all other variables contained in the model (age, sex, smoking 
history, alcohol use history, employment status, monthly all-source income, monthly cell 
phone expenditure and source of funding for ZuziMpilo care). For BMI, adjusted ORs were 
of lesser magnitude but maintained the clear dose response relationship. Compared to obese 
patients, overweight patients were more than twice as likely (aOR = 2.83 CI 1.06 – 7.52, p 
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= 0.037), normal weight patients were 3.7 times more likely (aOR = 3.72, 1.44 – 9.60, p = 
0.007) and underweight patients were more than six times more likely to have prevalent TB 
(aOR = 6.42, CI 2.33 – 17.70, p = 0.000). With respect to CD4 count, a CD4 count of < 200 
cells/mm
3 
predicted an 11.3 times increased risk of prevalent TB relative to  CD4 count 
greater than 350 cells/mm
3
 (aOR = 11.27, CI 4.84 – 26.28, p = 0.000). Patients exposed to 
HAART for longer than 6 months were significantly less likely to have prevalent TB than 
HAART-naïve patients (aOR = 0.47, CI 0.23 – 0.98, p = 0.043).  
 
Table 3-4: Univariate and multivariate analysis of characteristics influencing 
prevalent TB using logistic regression.  
 
Characteristic Crude OR  (95% CI) P value Adjusted OR  (95% CI) P value 
Age     
< 30 years  Reference  Reference   
30 to 39.9 years  1.46  (1.01 - 2.12) 0.043 1.27  (0.84 - 1.92) 0.255 
> 40 years  1.07  (0.67 - 1.71) 0.763 0.79  (0.48 - 1.31) 0.362 
Sex     
Female, n (%) Reference  Reference   
Male, n (%) 1.41  (1.01 - 1.95) 0.042 0.92  (0.62 - 1.39) 0.690 
Ethnicity     
Black Reference  Not included in model   
Coloured 2.14  (0.09 - 5.46) 0.747    
White 2.14  (0.46 - 9.89) 0.327    
Other Omitted     
Missing 0.44  (0.18 - 1.11) 0.083     
BMI     
Obese Reference  Reference   
Overweight 3.60  (1.38 - 9.34) 0.009 2.83  (1.06 - 7.52) 0.037 
Normal weight 5.90  (2.36 - 14.75) 0.000 3.72  (1.44 - 9.60) 0.007 
Underweight 13.98  (5.35 - 36.55) 0.000 6.42  (2.33 - 17.70) 0.000 
Missing 0.14  (0.12 - 1.21) 0.074 0.13  (0.01 - 1.13) 0.064 
WHO stage     
Stage 1 Reference  Not included in model  
Stage 2 1.91  (0.78 - 4.66) 0.157   
 50 
Characteristic Crude OR  (95% CI) P value Adjusted OR  (95% CI) P value 
Stage 3 11.61  (5.20 - 25.89) 0.000   
Stage 4 15.16  (6.54 - 35.10) 0.000   
Missing 1.73  (0.76 - 3.95) 0.193    
CD4 count   Reference    
>350 Reference  Reference   
201 to 350 3.48  (1.35 - 8.89) 0.009 2.79  (1.09 - 7.22) 0.034 
<200 18.71  (8.18 - 42.79) 0.000 11.27  (4.84 - 26.28) 0.000 
Missing 5.40  (1.84 - 15.83) 0.002 5.81  (1.94 - 17.45) 0.002 
HAART status     
HAART naïve Reference  Not included in model  
Stared HAART 0.72  (0.44 - 1.17) 0.183   
Months on HAART     
HAART naive Reference   Reference   
HAART < 6 months 1.64  (0.85 - 3.18) 0.140 1.26  (0.62 - 2.57) 0.524 
HAART > 6 months 0.43  (0.21 - 0.85) 0.015 0.47  (0.23 - 0.98) 0.043 
Smoking     
No smoking Reference  Reference   
<7 cigarettes/week 0.52  (0.21 - 1.290 0.159 0.52  (0.19 - 1.41) 0.198 
>7 cigarettes/week 1.68  (0.87 - 3.250 0.122 1.57  (0.72 - 3.42) 0.255 
Missing 1.30  (0.68 - 2.48) 0.435 1.62  (0.52 - 5.02) 0.403 
Alcohol use       
No alcohol Reference  Reference   
<6 drinks/week 0.56  (0.30 - 1.02) 0.059 0.80  (0.41 - 1.55) 0.504 
>6 drinks/week 0.91  (0.48 - 1.73) 0.774 1.00  (0.46 - 2.180 0.995 
Missing 1.00  (0.55 - 1.83) 0.990 1.12  0.36 - 3.49) 0.845 
Level of education     
Primary school Reference  Not included in model  
Secondary school 1.33  (0.69 - 2.560 0.390   
Tertiary education 0.92  (0.49 - 1.72) 0.784   
Missing 1.08  (0.45 - 2.59) 0.863    
Employment status     
Not unemployed

 Reference  Reference   
Unemployed 1.51  (1.04 - 2.18) 0.029 0.79  (0.39 - 1.61) 0.514 
Missing 0.46  (0.14 - 1.490 0.196 0.36  (0.10 - 1.32) 0.124 
Monthly income     
< R1,000 Reference  Reference   
R1,000 to R4,999 0.73  (0.48 - 1.16) 0.147 0.58  (0.27 - 1.250 0.164 
> R5,000 0.56  (0.35 - 0.880 0.012 0.63  (0.28 - 1.40) 0.254 
Missing 0.58  (0.34 - 0.97) 0.039 0.71  (0.13 - 3.77) 0.685 
Cell phone expenditure  
R0 to R200 Reference  Reference   
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Characteristic Crude OR  (95% CI) P value Adjusted OR  (95% CI) P value 
>R200 0.71  (0.44 - 1.14) 0.159 0.84  (0.50 - 1.43) 0.529 
Missing 0.79  (0.51 - 1.24) 0.304 0.80  (0.27 - 2.39) 0.696 
Medical Insurance       
Has medical insurance Reference  Not included in model  
No medical insurance 0.93  (0.52 - 1.66) 0.812   
Missing 0.79  (0.50 - 1.26) 0.327    
Financing of care       
Self-funded Reference  Reference   
Funded by other 2.09  (1.35 - 3.25) 0.001 1.14  (0.66 - 1.98) 0.633 
Missing 0.91  (0.58 - 1.42) 0.672 0.79  (0.25 - 2.51) 0.687 
Knowledge of service       
Workplace Reference    
Health facility 0.74  (0.27 - 1.98) 0.544 Not included in model  
Mass media 0.59  (0.22 - 1.59) 0.296   
Partner, family or friend 1.23  (0.47 - 3.24) 0.674   
Missing 0.75  (0.27 - 2.040 0.571   
 Not unemployed = employed (full-time, part-time and self-employed), pensioners and students 
 
3.4.5. Sensitivity Analysis 
The analysis was repeated using a dataset that included the 39 patients classified as 
“Suspected TB” in the case definition for prevalent TB. The results are shown in Appendix 
6.2. In this analysis, 195 patients have prevalent TB at enrolment, which translates into a 
prevalence rate of 10.30%. BMI, CD4 count, duration of exposure to HAART, current 
smoking history and the source of funding for ZuziMpilo care were found to be significant 
predictors of prevalent TB, adjusting for all the other variables contained in the model (age, 
sex, current alcohol use history, employment status, monthly all-source income, monthly 
cell phone expenditure and source of knowledge about ZuziMpilo).   
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4. DISCUSSION 
This chapter discusses the major findings of the study and their meaning and importance in 
relation to the findings of other studies. It addresses the relevance and generalisability of 
the findings and closes with a reflection on the limitations of the study.  
 
This study aimed to determine the prevalence of TB among HIV-positive patients enrolling 
at a fee-for-service, dedicated HIV clinic in downtown Johannesburg and to identify the 
factors that predict prevalent TB in this population. The findings were that 8.24% of adult 
ZuziMpilo clinic attendees who enrolled over a 29 month period between 1 August 2009 
and 31 December 2011 had prevalent TB at enrollment and that significant predictors for 
prevalent TB included  non-obese BMI, CD4 count <350 cells/mm
3
 and  duration on 
HAART of longer than six months.  
 
4.1. TB prevalence  
The TB prevalence at enrollment of 8.24% reported for this study approximates the 
prevalence of 8% reported in a study by Hanrahan et al for patients enrolling at an HIV 
Wellness clinic in Soweto in Gauteng province (40), but is markedly lower than TB 
prevalence reported for other dedicated HIV clinics, both within and outside Gauteng 
Province. For example, TB prevalence at enrolment was estimated at 42.5% (in 2007) and 
34.7% (in 2007/8) in the Western Cape Province townships Kayelitsha and Gugulethu 
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respectively (39, 43), at 23% (in 2004 to 2007) in suburban Johannesburg, Gauteng 
province and at 20% (in 2007/8) in suburban Durban, KwaZulu-Natal province (33, 39). 
There are several potential explanations for these differences, including; varying regional 
TB rates (the prevalence of TB is relatively higher in Western Cape townships), varying 
regional HIV burdens, the varying thoroughness of TB screening and varying case 
definitions for prevalent TB (the case definitions for all the studies broader than the case 
definition used in this study). However, the most influential factor is likely to be the 
differing levels of immunosuppression at enrolment, reflected in the median CD4 count 
measurements. The two studies that report the lowest TB prevalence (approximately 8%) 
also report the highest median CD4 counts. Specifically, the median CD4 count for this 
study was 239 cells/mm
3 
(IQR 110 – 405) while the median CD4 count for the study at a 
non-fee paying HIV Wellness clinic at a tertiary public sector hospital in Soweto was 285 
cells/mm
3
 (153 – 452). In comparison, the other four studies, conducted in Kayelitsha, 
Gugulethu, Johannesburg and Durban reported median CD4 counts that ranged from 42 to 
131 cells/mm
3 
and TB prevalence rates that ranged from 16% to 43%.  
 
4.2. Predictors of TB 
In terms of factors that predict prevalent TB, the results of this study are consistent with the 
findings of several other published studies.  
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4.2.1. CD4 count  
In this study, compared to CD4 counts greater than 350 cells/mm
3
, CD4 counts of < 200 
cells/mm
3 
predicted an 11.3 fold increased risk of prevalent TB (aOR = 11.27, CI 4.84 – 
26.28, p = 0.000) and CD4 counts ranging from 201 to 350 cells/mm
3 
predicted an 2.8 fold 
increased risk of prevalent TB (aOR = 2.79, CI 1.09 – 7.22, p = 0.034). These results are 
consistent with well-established findings of numerous prior studies that have identified 
advanced immunodeficiency (low CD4 count) as one of the most important risk factors for 
TB (38, 39, 41, 54, 55).  
 
4.2.2. Body Mass Index 
In this analysis, individuals who were not obese had greater risk of prevalent TB, the risk 
increasing in a dose response fashion as the BMI decreased. These findings are consistent 
with the findings of a number of studies that identify BMI as a strong, independent risk 
factor for mortality and tuberculosis among HIV infected adults (40, 62, 63, 66). One of 
these studies was designed to elucidate the relationship between BMI and all-cause 
mortality and incident TB among HIV infected adults. The study, conducted by Hanrahan 
et al showed a clear protective effect of increasing BMI on incident TB, also with a dose 
response, in 3635 HIV-infected adults attending a Soweto HIV wellness clinic.(40)   
In the current study, the magnitudes of the ORs for overweight, normal weight and 
underweight BMIs yielded by multivariable analysis are markedly greater than those 
yielded by univariate analysis. For example, in the univariate analysis, an underweight 
person is almost 14 times more likely (OR = 13.98, CI 5.35 – 36.55) to have prevalent TB 
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than an obese person. In the multivariable analysis, however, the aOR drops to less than 
half this OR, i.e., an underweight person is just over 6 times more likely to have prevalent 
TB, taking into account all the variables included in the model.
1
 Likely potential 
confounders in this model include sex, age and CD4 count. Controlling for confounding is 
especially critical when doing a cross-sectional evaluation of this nature because weight 
loss, and thus decreasing BMI, is a classic sign of both TB and advancing HIV disease. 
Thus the biological mechanism behind a single measure of low BMI is hard to evaluate  
(40). Without serial measurements it is difficult to assess whether the current BMI is lower 
than “normal” for a patient and if so, if it is a sign of TB and/or a sign of progressive HIV 
disease.  On the other hand, it could be the current nutritional status of obese patients 
relative to those with lower BMIs that is driving the apparent protective effect. By 
including CD4 count in the multivariable model it was possible to tease out the contribution 
of underlying immunodeficiency and illness to the BMI and thus the contribution of obesity 
and higher BMIs to reduction of the risk of prevalent TB.  
 
4.2.3. Duration of HAART  
This analysis confirms the effectiveness of long-term HAART in reducing the incidence of 
TB among HIV-positive individuals in sub-Saharan Africa (67-69). Although TB 
prevalence did not vary significantly between those on and off HAART, when it was 
                                                 
1
 age, sex, CD4 count, smoking history, alcohol use history, employment status, monthly all-source income, 
monthly cell phone expenditure and source of funding for ZuziMpilo care 
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analysed in terms of the duration of exposure to HAART, patients who had been on 
HAART for longer than 6 months at their first visit to ZuziMpilo were 53% less likely to 
have prevalent TB than HAART-naïve patients (aOR = 0.47, 95% CI 0.23 – 0.98, P = 
0.043), after adjusting for age, sex, BMI, CD4 count, alcohol and tobacco consumption 
history, monthly all-source income, source of funding for ZuziMpilo care and source of 
knowledge about ZuziMpilo. This result is consistent with the well-established finding that 
TB incidence remains high in the first few months following HAART initiation – a 
combination of prevalent disease missed at baseline screening, including subclinical TB 
unmasked by the initial rapid restoration of the immune system (TB IRIS), and new 
infections (45, 67, 83). Over time HAART restores CD4 cell function and numbers and the 
risk of TB declines - although it never reaches the levels associated with HIV seronegative 
individuals. This association between CD4 count and duration of HAART is evident in this 
study; significantly fewer patients who had been on HAART for 6 months (26.2%) had 
profound immunosuppression (CD4 count < 200 cells/mm
3)
, compared to those who had 
been on HAART for less than 6 months (46.3%), (P = 0.000).  
 
4.2.4. Poor socio-economic status 
This study did not find an independent association between socioeconomic markers and 
prevalent TB. It is possible that socioeconomic status is not fully captured in the variables 
used in this study; monthly income, monthly cell phone expenditure and ability to fund own 
ZuziMpilo care. However, the more likely reason is that the population of patients who 
seek care at ZuziMpilo by definition fit into a higher socioeconomic bracket that is not 
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exposed to the socioeconomic factors that independently predispose to TB risk. Access to 
alternative economic resources that buffer them from these factors is implied by the fact 
that they attend a fee-paying service, even for those who are unemployed and/or unable to 
pay for their own ZuziMpilo care.  
 
4.2.5. Smoking and alcohol consumption 
It is not surprising that there was no association, even in the unadjusted analysis, between 
current alcohol and tobacco use history and the risk of prevalent TB in this study given the 
poor quality of the data captured and the fact that there were very few patients who reported 
heavy exposure. The poor data quality of the data for these variables and the strong 
suggestion of reporter bias are discussed in detail under the section on limitations below. 
 
4.3. Strengths and limitations 
The strengths and limitations of this study are discussed with respect to the classification of 
the outcome and exposure variables, the management of confounding, and the relevance 
and generalisability of the results: 
4.3.1. Classification of variables: 
The case definition for prevalent TB in this study was specific, including only cases with 
laboratory evidence for M. tuberculosis, or, failing this, evidence of clinical recovery 
(symptoms and signs) after commencement of TB treatment. Therefore, unlike several 
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other TB prevalence studies discussed in this report that used broader case definitions, it is 
unlikely that patients with TB at their first clinic visit were overstated, increasing the 
validity of the independent associations observed. It is possible, however that the estimate 
of TB prevalence underestimates the true prevalence, partly because sputum microscopy is 
less sensitive in HIV-infected patients (24, 25) and partly because clinical diagnoses of TB 
made at ZuziMpilo were frequently not followed by laboratory confirmation, though 
seeking laboratory confirmation is considered standard practice at the clinic. This 
introduces an element of measurement bias. Moreover, it is possible that the prevalence of 
TB at enrollment would increase if there had been appropriate source document 
information available, chiefly laboratory reports and clinical findings from follow up visits, 
for the 39 patients for whom there was insufficient evidence for a definitive classification 
according to the study case definition.  
 
There are potential sources of error in data collection that may have led to misclassification 
of exposure variables and undermined the quality of some variables more than others. This 
study was an observational retrospective study using secondary data generated by an 
electronic patient management tool, TherapyEdge
TM
, which was not designed as a research 
data capture tool. Despite the numerous built-in logical and range checks, missing values, 
implausible values and errors in units of measurement were present. This is compounded by 
the fact that data were entered once in real time by multiple users at any one visit and not 
subjected to quality audits. Data concerning alcohol and tobacco use were particularly 
affected. For example, in response to the question asked at enrollment, “How many 
cigarettes do you smoke per week?” data entries included responses as variable as: 
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“4/month”, “4 per w” or numbers without units of measurement. This lack of clarity makes 
it difficult to interpret the responses and undermines confidence in the accuracy of the data 
and hence the validity of the results observed. Confidence in the accuracy is further 
undermined by a strong suspicion of reporter bias, i.e., participants underreporting their 
smoking behaviour. This is suggested by the high number of patients reporting themselves 
to be non-smokers (83.8%) and the relatively modest number of cigarettes reportedly 
smoked per week (4.5% of participants reported smoking more than 7 cigarettes per week).  
 
With regard to the analysis of missing values (Appendix 6.1), it makes sense that patients 
for whom a value for WHO Stage had been recorded had a significantly higher prevalence 
of TB than patients with missing values for WHO Stage (P < 0.050) because a diagnosis of 
pulmonary or extra pulmonary TB is a key and common staging condition for WHO Stages 
3 and 4 respectively. This variable was excluded from the multivariable logistic regression.  
With BMI, patients for whom both height and weight were recorded had a significantly 
higher prevalence of TB than patients with missing values (P < 0.050), which may suggest 
that clinicians at ZuziMpilo were motivated to take or record anthropometric measurements 
for reasons related to the outcome variable, for example, because the patient already had a 
diagnosis of TB at enrollment or because the patient appeared to be unwell. Despite this 
significant association, the missing data did not bias results of the analysis because missing 
data were assigned a unique category in each variable.  
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4.3.2. Management of confounding 
Multivariable logistic regression was used to manage the potentially biasing effect of 
confounding variables. There remains the possibility that there are unmeasured confounders 
that exert bias on the findings. For example, data about haemoglobin levels were not 
collected and included in the analysis and it is possible that anaemia could be an 
unmeasured confounder in the relationship between BMI and the outcome of interest. 
However, the significance and magnitude of the independent associations observed in this 
study are coherent with published reports of analyses that have included anaemia as a 
variable and it is unlikely that possible residual confounding in this study would change 
these findings substantially. 
 
4.3.3. Relevance and generalisability of the results 
This study has describes a unique population with the capacity to pay a subsidised monthly 
fee for their HIV care. Thus, the study sample may not be generalisable to the large 
population of HIV-infected adults in South Africa, who receive free health care in public 
sector facilities. This is certainly true of the lack of an independent association observed 
between different levels of socio economic markers and the prevalence of TB at enrollment. 
These findings may certainly be more generalisable to other clinics that provide services for 
a subsidized monthly fee and this information may be especially important if this model is 
replicated and scaled up in private and semi-private facilities around the country.  
However, this study has great clinical relevance because it corroborates the growing body 
of evidence that underpins several key recommendations that have the potential to reduce  
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mortality from TB in those people infected with HIV; vigilant and regular routine TB 
screening in HIV-infected patients at all CD4 counts and especially in those with profound 
immunosuppression and in the first three to four months following HAART initiation, the 
urgent development and distribution of more sensitive and point of care diagnostic tests for 
TB in HIV-infected patients at all levels of health care (most especially primary health care 
facilities) and the importance of  initiation of HAART in individuals with active 
tuberculosis regardless of WHO clinical stage or CD4 count  This study also highlights the 
importance of regular, routine anthropometric measurement, even in relatively affluent 
populations. 
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5. CONCLUSION 
 
This study found that approximately 8 out of every 100 HIV-infected adults enrolling at a 
fee-for-service dedicated HIV clinic in downtown Johannesburg had prevalent TB disease. 
This was a relatively healthy population, as indicated by the median CD4 count, and this 
prevalence approximates to that estimated in a non-fee-paying clinic population in Soweto, 
Gauteng with similar levels of immunosuppression. Profound immunosuppression, non-
obese and decreasing BMI and less than 6 months exposure to HAART were confirmed as 
powerful predictors of TB risk among HIV-infected individuals in a relatively affluent 
setting.  This study highlights that BMI is a useful proxy marker of TB risk among HIV-
positive individuals. Height and weight are easily assessed anthropomorphic measures and 
should be conducted routinely in all patients at regular intervals.  
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6. APPENDIX 
6.1. Analysis of missing values  
The Chi-squared test was used to investigate whether missing data in each variable were 
associated with the outcome (Prevalent TB) in order to assess potential sources of bias and 
how these could be dealt with. Missing data for the variables WHO Clinical Stage and BMI 
were associated with Prevalent TB. The potential influence of these associations and 
measures taken to minimize bias are covered in the discussion. 
 
Table 6-1: Analysis of the association between missing values for each variable and Prevalent 
TB using the Chi-squared test  
Characteristic No TB Prevalent TB P value 
  N % N % 
Ethnicity           
Non-missing 1617 91.46 151 8.54 
0.090 
Missing 120 96.00 5 4.00 
BMI           
Non-missing 1408 90.08 155 9.92 
0.000 
Missing 329 99.70 1 0.30 
WHO stage           
Non-missing 948 88.60 122 11.40 
0.000 
Missing 789 95.87 34 4.13 
CD4 count             
Non-missing 1602 91.54 148 8.46 
0.231 
Missing 135 94.41 8 5.59 
Smoking           
Non-missing 1602 91.81 143 8.19 
0.403 
Missing 135 91.22 13 8.78 
Alcohol use             
Non-missing 1641 91.88 145 8.12 
0.802 
Missing 96 89.72 11 10.28 
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Characteristic No TB Prevalent TB P value 
  N % N % 
Level of education           
Non-missing 1629 91.77 146 8.23 
0.924 
Missing 108 91.53 10 8.47 
Employment status           
Non-missing 1659 91.56 153 8.44 
0.129 
Missing 78 96.30 3 3.70 
Monthly income           
Non-missing 1422 91.45 133 8.55 
0.289 
Missing 315 93.20 23 6.80 
Monthly cell phone expenditure 
Non-missing 1405 91.53 130 8.47 
0.455 
Missing 332 92.74 26 7.26 
Medical Insurance             
Non-missing 1428 91.48 133 8.52 
0.338 
Missing 309 93.07 23 6.93 
Financing of care             
Non-missing 1389 91.44 130 8.56 
0.312 
Missing 348 93.05 26 6.95 
Knowledge of service             
Non-missing 1398 91.55 129 8.45 
0.503 
Missing 339 92.62 156 7.38 
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6.2. Sensitivity Analysis:  
Analysis with alternative dataset that includes the 39 patients classified as “Suspected TB” 
in the study case definition: 195 patients with prevalent TB 
Table 6-2: Associations between patient characteristics and Prevalent TB  
Characteristic Prevalent TB 
(n=195) 
No TB 
(n=1698) P value

 
Age Median (IQR) Median (IQR)  
 33  (28 – 39) 31  (26 – 38) 0.030 

 
Age N  (%) N  (%)  
< 30 years  62 (8.19) 695 (91.81) 0.035 
30 to 39.9 years  90 (12.24) 645 (87.76)  
> 40 years  43 (10.72) 358 (89.28)  
Sex    
Female, n (%) 97 (8.51) 1043 (91.49) 0.002 
Male, n (%) 98 (13.01) 655 (86.99)  
Ethnicity    
Black 184 (10.59) 1553 (89.41) 0.268

 
Coloured 2 (12.50) 14 (87.50)  
White 2 (16.67) 10 (83.33)  
Other 0 (0.00) 3 (100.00)  
Missing 7 (5.60) 118 (94.40)  
BMI    
Obese 6 (2.54) 230 (97.46) 0.000 
Overweight 41 (8.97) 416 (91.03)  
Normal weight 102 (14.27) 613 (85.73)  
Underweight 42 (27.10) 113 (72.90)  
Missing 4 (1.21) 326 (98.79)  
WHO stage    
Stage 1 7 (2.43) 281 (97.57) 0.000 
Stage 2 22 (5.87) 353 (94.13)   
Stage 3 80 (29.41) 192 (70.59)   
Stage 4 48 (35.56) 87 (64.44)   
Missing 38 (4.62) 785 (95.38)   
CD4 count      
>350 9 (1.63) 544 (98.37) 0.000 
201 to 350 20 (4.32) 443 (95.68)   
<200 154 (20.98) 580 (79.02)   
Missing 12 (8.39) 131 (91.61)   
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Characteristic Prevalent TB 
(n=195) 
No TB 
(n=1698) P value

 
HAART status    
HAART naïve 170 (10.77) 1408 (89.23) 0.130 
Stared HAART 25 (7.94) 290 (92.06)  
Months on HAART    
HAART naive 170 (10.77) 1408 (89.23) 0.002 
HAART < 6 months 14 (17.070 68 (82.93)  
HAART > 6 months 11 (4.72) 222 (95.28)  
Smoking    
No smoking 162 (10.21) 1425 (89.79) 0.096 
<7 cigarettes/week 6 (5.26) 108 (94.74)  
>7 cigarettes/week 13 15.290 72 (84.710  
Missing 14 (13.08) 93 (86.92)  
Alcohol use      
No alcohol 144 (10.50) 1227 (89.50) 0.394 
<6 drinks/week 18 (7.59) 219 (92.41)  
>6 drinks/week 15 (10.95) 122 (89.05)  
Missing 18 (12.16) 130 (87.84)  
Level of education    
Primary school 18 (11.84) 134 (88.16) 0.211 
Secondary school 65 (12.10) 472 (87.90)  
Tertiary education 98 (9.02) 988 (90.98)  
Missing 14 (11.82) 104 (88.14)  
Employment status    
Not unemployed

 133 (9.38) 1285 (90.62) 0.006 
Unemployed 57 (14.47) 337 (85.53)  
Missing 5 (6.17) 76 (93.83)  
Monthly income    
< R1,000 59 (14.43) 350 (85.570 0.020 
R1,000 to R4,999 58 (9.67) 542 (90.33)  
> R5,000 48 (8.79) 498 (91.21)  
Missing 30 (8.88) 308 (91.12)  
Cell phone expenditure 
R0 to R200 136 (11.33) 1064 (88.67) 0.103 
>R200 25 (7.460 310 (92.54)  
Missing 34 (9.50) 324 (90.50)  
Medical Insurance      
Has medical insurance 148 (10.67) 1239 (89.33) 0.581 
No medical insurance 18 (10.34) 156 (89.66)  
Missing 29 (8.73) 303 (91.27)  
Financing of care      
Self-funded 119 (9.05) 1196 (90.95) 0.000 
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Characteristic Prevalent TB 
(n=195) 
No TB 
(n=1698) P value

 
Funded by other 43 (21.08) 161 (78.92)  
Missing 33 (8.82) 341 (91.18)  
Knowledge of service      
Workplace 8 (15.38) 44 (84.62) 0.000 
Health facility 39 (8.59) 415 (91.41)  
Mass media 33 (6.93) 443 (93.07)  
Partner, family or friend 81 (14.86) 464 (85.14)  
Missing 34 (9.29) 332 (90.71)  
 
 All P values are for Pearson’s 2 test for categorical variables except where indicated otherwise. 
 Student’s t-test for a normally distributed continuous variable 
 Fisher’s exact test 
 Not unemployed = employed (full-time, part-time and self-employed), pensioners and students 
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Table 6-3: Univariate and multivariate analysis of characteristics influencing prevalent TB using 
logistic regression. 
Characteristic Crude OR  (95% CI) P value Adjusted OR  (95% CI) P value 
Age     
< 30 years  Reference  Reference   
30 to 39.9 years  1.56  ( 1.11 – 2.20) 0.010   1.36  (0.93 – 2.00) 0.116 
> 40 years  1.35  ( 0.89 – 2.02) 0.154   0.98  (0.62 – 1.55) 0.930 
Sex     
Female, n (%) Reference  Reference   
Male, n (%) 1.61  (1.19 – 2.17) 0.002   1.07  (0.74 – 1.55) 0.707 
Ethnicity     
Black Reference  Not included in model   
Coloured 1.20  (0.27 – 5.35) 0.806    
White 1.69  (0.37 – 7.76) 0.501    
Other omitted     
Missing 0.50  (0.23 – 1.10) 0.081     
BMI     
Obese Reference  Reference   
Overweight 3.78  (1.58 - 9.03) 0.003   3.00  (1.22 – 7.41) 0.017 
Normal weight 6.38  (2.76 – 14.73) 0.000   4.10  (1.71 – 9.84) 0.002 
Underweight 14.25 (5.88 – 34.51) 0.000   6.07  (2.36 – 15.56) 0.000 
Missing 0.47  (0.13 – 1.67) 0.247   0.42  (0.11 – 1.56) 0.195 
WHO stage     
Stage 1 Reference  Not included in model  
Stage 2 2.50  (1.05 – 5.94) 0.038     
Stage 3 16.73  (7.56 – 37.00) 0.000     
Stage 4 22.15  (9.67 – 50.72) 0.000     
Missing 1.94  (0.86 – 4.400 0.111      
CD4 count   Reference    
>350 Reference  Reference   
201 to 350 2.73  (1.23 – 6.05) 0.014   2.05  (0.91 – 4.61) 0.083 
<200 16.05  (8.11 – 31.75) 0.000   9.03  (4.47 – 18.22) 0.000 
Missing 5.54  (2.29 – 13.42) 0.000   5.35  (2.14 – 13.38) 0.000 
HAART status     
HAART naïve Reference  Not included in model  
Stared HAART 0.71  (0.46 – 1.12) 0.132   
Months on HAART     
HAART naive Reference   Reference   
HAART < 6 months 1.71  (0.94 – 3.10) 0.080 1.21  (0.62 – 2.36) 0.569 
HAART > 6 months 0.41  (0.22 – 0.77) 0.005 0.46  (0.24 – 0.90) 0.023 
Smoking     
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Characteristic Crude OR  (95% CI) P value Adjusted OR  (95% CI) P value 
No smoking Reference  Reference   
<7 cigarettes/week 0.49  (0.21 – 1.13) 0.094 0.38  (0.15 – 0.97) 0.042 
>7 cigarettes/week 1.59  (0.86 – 2.93) 0.139 1.25  (0.60 – 2.61) 0.548 
Missing 1.32  (0.74 – 2.38) 0.346 1.25  (0.47 – 3.38) 0.655 
Alcohol use       
No alcohol Reference  Reference   
<6 drinks/week 0.70  (0.42 – 1.18) 0.172 1.03  (0.58 – 1.83) 0.930 
>6 drinks/week 1.05  (0.60 – 1.84) 0.871 1.18  (0.58 – 2.39) 0.644 
Missing 1.18  (0.70 – 1.99) 0.535 1.58  (0.58 – 4.26) 0.369 
Level of education     
Primary school Reference  Not included in model  
Secondary school 1.03  (0.59 – 1.79) 0.930     
Tertiary education 0.74  (0.43 – 1.26) 0.266     
Missing 1.00  (0.48 – 2.11) 0.996      
Employment status     
Not unemployed

 Reference  Reference   
Unemployed 1.63  (1.17 – 2.28) 0.004 0.80  (0.42 – 1.55) 0.517 
Missing 0.64  (0.25 – 1.60) 0.336 0.52  (0.18 – 1.50) 0.228 
Monthly income     
< R1,000 Reference  Reference   
R1,000 to R4,999 0.63  (0.43 – 0.93) 0.021   0.64  (0.31 – 1.31) 0.222 
> R5,000 0.57  (0.38 – 0.86) 0.007   0.85  (0.40 – 1.80) 0.673 
Missing 0.58  (0.36 – 0.92) 0.021   0.54  (0.10 – 3.02) 0.483 
Cell phone expenditure  
R0 to R200 Reference  Reference   
>R200 0.63  (0.40 – 0.98) 0.042   0.76  (0.46 – 1.25) 0.280 
Missing 0.82  (0.55 – 1.22) 0.329   0.99  (0.36 – 2.71) 0.982 
Medical Insurance       
Has medical insurance Reference  Not included in model  
No medical insurance 0.97  (0.58 – 1.62) 0.895   
Missing 0.80  (0.53 – 1.22) 0.298    
Financing of care       
Self-funded Reference  Reference   
Funded by other 2.68  (1.83 – 3.95) 0.00   1.71  (1.03 – 2.84) 0.039 
Missing 0.97 (0.65 – 1.46) 0.893   0.72  (0.23 – 2.25) 0.574 
Knowledge of service       
Workplace Reference  Reference  
Health facility 0.52  (0.23 – 1.18) 0.115   0.74  (0.30 – 1.83) 0.513 
Mass media 0.41  (0.18 – 0.94) 0.036   0.73  (0.29 – 1.85) 0.512 
Partner, family or friend 0.96  (0.44 – 2.11) 0.920   1.21  (0.50 – 2.95) 0.670 
Missing 0.56  (0.25 – 1.29) 0.176   1.21  (0.32 – 4.49) 0.778 
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6.3. Assessment of collinearity between exposure variables using the Spearman’s 
correlation test 
 Sex Age CD4 count WHO Stage BMI 
Level of 
education 
       
Sex 1      
Age 0.1749 1     
CD4 count 0.1192 0.0648 1    
WHO Stage -0.009 -0.0429 -0.1052 1   
BMI 0.134 -0.0831 0.0752 0.3161 1  
Level of education -0.0463 -0.1857 -0.0541 0.0521 -0.0121 1 
Employment status 0.0818 0.0224 -0.0381 0.0378 -0.0464 0.127 
Monthly income 0.106 -0.0025 0.0007 0.0461 -0.0243 0.1211 
Monthly cell phone expenditure 0.0764 -0.0351 0.0322 0.0094 -0.0139 0.0366 
Knowledge of service 0.0307 0.002 0.0631 0.0676 0.0912 -0.0267 
Financing of care -0.0059 0.0135 0.0974 -0.0023 0.0521 -0.123 
Medical Insurance 0.0033 -0.0281 0.0208 0.0585 0.0275 0.0382 
 
 
Employment 
status 
Monthly 
income 
Cell phone 
expenditure 
Knowledge 
of service 
Financing 
of care 
Medical 
Insurance 
       
Sex       
Age       
CD4 count       
WHO Stage       
BMI       
Level of education       
Employment status 1      
Monthly income 0.5533 1     
Monthly cell phone expenditure 0.2304 0.6075 1    
Knowledge of service 0.0708 0.4033 0.4797 1   
Financing of care -0.0088 0.3877 0.5429 0.5137 1  
Medical Insurance 0.2345 0.6842 0.6296 0.5524 0.6239 1 
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